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ABSTRACT

Bydalek, Shawn. The Synthesis and Characterization of 2-Arachidonoyl Glycerol.
Unpublished Master of Science thesis, University of Northern Colorado, 2019

Cannabinoids are a structurally diverse class of compounds that act as ligands at
the cannabinoid receptors, CB1 and CB2, through which the majority of the physiological
effects of these compounds are mediated. Endocannabinoids (endogenous cannabinoids)
are a subset of the cannabinoid family and include 2-arachidonoyl glycerol (2-AG) and
N-arachidonoyl ethanolamide, and like most cannabinoids, these compounds have been
shown to have anti-neoplastic effects on various cancer lines. The synthesis of 2-AG
from dihydroxyacetone was selected as a research goal to try to improve yield over older
published synthetic methods, to keep 2-AG in a protected form to avoid isomerization
and other unwanted side reactions, and ultimately to experiment with further chemical
modification of 2-AG and observe how this affects its anti-neoplastic activity. The
methodology employed used the silyl ether protecting reagent t-BDPSiCl and yields up to
the esterification step were excellent. Esterification with SOCl2 did not return yields on
par with previous steps, but improvements in yield were seen by increasing reaction
temperature. Analysis of deprotection was complicated by difficulties with the HPLC
methodology, but the protecting group was found to be amenable to a single flask
synthesis in DMF using SOCl2, which is a highly appealing quality to this methodology.
iii
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CHAPTER I
INTRODUCTION
History
Cannabis sativa, colloquially referred to as marijuana, is a flowering plant which
has been utilized medicinally, ceremonially, and recreationally across various cultures
and times (Lambert & Fowler, 2005). Inhalation of smoke from the plant or using the
plant material in food preparation (baking) and then consuming that food leads to
psychoactive effects, generally characterized as a sensation of euphoria and has been
linked with various other physiological outcomes, such as stimulation of appetite or
attenuation of short-term memory. The underlying mechanism by which these effects
were mediated remained a mystery for over half of the twentieth century, owing primarily
to difficulties in isolating and purifying the individual components in crude extracts. This
changed in 1964 when Raphael Mechoulam and his research team from the Hebrew
University in Jerusalem isolated and characterized the first psychoactive constituent
(-)-Δ1-tetrahydrocannabinol or (-)-THC, or simply THC (see Figure 1 for the Δ1
numbering scheme used by Mechoulam and Figure 2 for the Δ9 numbering scheme also
commonly used by Cannabis researchers) from C. sativa (Gaoni & Mechoulam, 1964).
The elucidation of the structure of THC reinvigorated the research involving marijuana
and the chemical constituents of the plant, at least abroad.
The history of marijuana use and regulation in the United States is characterized
by turbidity. Passage of the Marihuana Tax Act in 1937 brought marijuana directly under
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federal purview, an action that was railed against by many for its apparent intention to
sabotage the hemp industry, in addition to its other primary purpose to act as a legal
cudgel to prosecute specific populations of recreational users, primarily poor black
farmers who were singled out for being "deviant." The subsequent passage of the
Controlled Substances Act in the latter part of 1970 classified marijuana as a Schedule I
substance, labeling it as a substance with "no currently accepted medical use and high
potential for abuse". As a consequence of these social mores, research of marijuana in the
U.S. languished (Peters & Nahas, 1992).

Figure 1. Δ1 Numbering scheme for THC.

Figure 2. Δ9 Numbering scheme for THC.
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Nonetheless, progress continued apace, although not without new challenges. The
primary problem confronting Cannabis researchers was determining how these
compounds were eliciting their physiological effects. Initially it was presumed that,
owing to the hydrophobic nature of THC and other major Cannabis constituents,
physiological activity was affected primarily through non-specific interactions with
cellular membranes, similar to general anesthetics such as halothane (Petrocellis & Di
Marzo, 2009). In addition, early research conducted with synthesized (+)-THC showed
comparable activity with that of naturally occurring (-)-THC, which provided further
evidence that bioactivity of THC was probably owed to non-specific interactions of some
sort (Dewey, Martin, & May, 1984). However, other research conducted by Mechoulam
indicated that the activity of THC was, in fact, enantioselective. Mechoulam's group
published results in 1980 demonstrating that (-)-THC exhibited psychoactivity in rhesus
monkeys at 50 µg/kg, while (+)-THC showed no activity at 1 mg/kg (Mechoulam et al.,
1980). These results strongly suggested that the physiologically active components of
marijuana were acting at a specific receptor, or possibly some specific membrane
element. Confirmation of this did not come until 1988, when Devane and colleagues used
[3H]CP-55, 940 (Figure 3), a THC analogue with less hydrophobic nature, to identify a
G-protein coupled receptor in rat brain that inhibits adenylate cyclase activity in a dosedependent, stereoselective manner, indicating that the receptor was of the Gi/o sub-type
(Devane, Dysarz, Johnson, Melvin, & Howlett, 1988).
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Figure 3. CP-55,940, a potent CB1 agonist.

The receptor was subsequently screened out of the library of orphan G-protein
coupled receptors and designated cannabinoid receptor 1 (CB1) by Matsuda and
colleagues (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990). The location of the
receptor and its specificity for THC made it the leading candidate for the mediator of the
psychoactive effects of marijuana. Later another cannabinoid receptor, dubbed CB2, was
identified through homology cloning and was found to be surprisingly disparate from
CB1 in its amino acid sequence, with just 44% overall sequence similarity, although this
jumps to 68% when considering transmembrane domains only (Munro, Thomas, & AbuShaar, 1993). Whereas CB1 is primarily located in the brain, CB2 was found to be located
primarily in immune tissues (spleen, tonsils, lymph nodes, and in various leukocytes) and
is presumed to be the key element in the immune suppressing effect of cannabinoids
(Flygare & Sander, 2008). The identification of these receptors rationalized the
stereospecificity of THC challenge as detailed previously, but it did not repudiate the
possibility that non-specific interactions played some element in physiological outcomes
for cannabinoid use, and indeed, that interaction is still presumed to play at least some
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role in the physiological effects (Makriyannis, 1995). Furthermore, the potential cellular
targets of cannabinoids are not exhausted by the identification of these two receptors, and
further research has vetted several other potential cellular targets which do not bear
further discussion at this point. In the aftermath of identification of these two receptors,
there was an obvious question: if there is an exogeneous compound which activates a
naturally occurring receptor, what is the endogenous counterpart?
An answer to this question came in 1992 when William Devane and his
colleagues published a paper on the isolation and structure of a brain constituent that
demonstrated activity at the cannabinoid receptors (Devane et al., 1992). The compound
was an arachidonic acid derivative, arachidonylethanolamide (Figure 4), named
"anandamide" by its discoverers (from the Sanskrit word "ananda" which means bliss).
Three years later, another arachidonic acid derivative, 2-arachidonoyl glycerol (Figure 5),
was identified almost simultaneously by Mechoulam (Mechoulam et al., 1995) and
Sugiura (Sugiura et al., 1995) as having activity at the cannabinoid receptors. These two
compounds constituted the first members of a new sub-class of cannabinoids, the
endocannabinoids, and since their discovery numerous other compounds have been added
to this sub-class (Figure 6).
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Figure 4. Arachidonyl ethanolamide (anandamide).

Figure 5. 2-Arachidonoyl glycerol (2-AG).

Figure 6. Additional endocannabinoids.
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Identification of natural ligands for the cannabinoid receptors effectively
canonized a new signaling system, and re-primed interest in cannabinoids and their
pharmacological effects. One of the earliest noted, and surprisingly overlooked, of these
effects was the concentration-dependent growth inhibition of Lewis lung adenocarcinoma
xenografts in mice (Munson, Harris, Friedman, Dewey, & Charchman, 1975). Results
from research conducted to examine the effects of marijuana use on intact cell and cell
component integrity, such as a study where the prevalence of chromosome breakage in
marijuana smoking vs. non-smoking groups was observed across a group of 60 total
individuals (Stenchever, Kunysz, & Allen, 1974), indicated that marijuana use had
deleterious effects on replicative elements of the cell. For instance, in the Stenchever
study, there were approximately 2-3 times as many incidences of chromosome breakage
in groups that smoked marijuana versus those that did not, irrespective of the amount of
self-reported use of marijuana and the use of potentially interfering agents (caffeine,
tobacco, etc.). In the case of the Munson experiment, treatment with 100 mg/kg of THC
across a period of 30 days increased mean survival time for murine specimens with
xenografts by 36% compared to controls. The results of the Munson study were
essentially disregarded despite their success, being succeeded by research investigating
the palliative uses for cannabinoids (Lucas Jr. & Lazlo, 1980), which to date are the only
therapeutic uses for which THC can be prescribed (Bifulco & Di Marzo, 2002). In light
of the current medical landscape, this seems like either an egregious oversight or a tragic
choice. According to the WHO's fact sheet (http://www.who.int/mediacentre/factsheets
/fs297/en/), cancer is the second leading cause of death in the world as of 2015, and the
probability that it will eventually become number one is extremely high, given that age is
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a major risk factor for cancer development, and the median age of U.S. citizens has
continued to rise steadily with time (https://www.census.gov/library/visualizations/2017
/comm/median-age.html).
Regardless of the direction of research in the past, the last two decades have been
replete with studies confirming the anti-cancer effects of cannabinoids across a wide
variety of cancer cell types, including glioma (Salazar et al., 2009), pancreatic (Carracedo
et al., 2006), breast (Caffarel et al., 2010), and a diverse array of other cancer types
(Velasco, Sanchez, & Guzman, 2012). The seemingly ubiquitous effect of cannabinoids
to impede growth, induce cell death, and inhibit invasiveness of cancer across a wide
range of sub-types indicates an extremely promising avenue to explore for developing
new treatment modalities for a disease which by its very nature demands treatment
methods that balance efficacy with quality of life considerations (Cella & Cherin, 1988).
This is a monumental task, and its difficulties are compounded by the reality that many
standard treatment methods are non-specific and can inadvertently cause further damage,
or even novel neoplasias themselves (Patrick, 2013). Considering these challenges,
cannabinoids are attractive as potential treatment formulations on their own or as part of a
comprehensive treatment package to ameliorate undesirable side effects, improve
selectivity in treatment outcomes, and improve overall quality of life for patients.
Statement of Difficulties and The
Research Goal
The process of rigorously evaluating the potential for cannabinoids to act as anticancer agents requires that they be gathered or synthesized in sufficient amounts for
further experimental use. This presents little challenge for evaluating phytocannabinoids,
since marijuana can be grown relatively easily (acquisition of which is only limited by
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Federal law), and the pertinent components can be extracted through simple solid phase
extraction and then purified. The endocannabinoids present a more formidable challenge,
as extraction from organic material is limited by the concentration present in tissue,
typically in the nmol/g or even pmol/g range, and in some cases below the limits of
detection (Mechoulam, Fride, & Di Marzo, 1998). Limited bioavailability could explain
(in part at least) why the cost for 5 mg of 2-arachidonylglycerol is $300.00 from SigmaAldrich as of 3/31/18 (https://www.sigmaaldrich.com/catalog/product/sigma/a8973?lang
=en& region=US), whereas arachidonic acid (20:45,8,11,14) is concurrently priced at
$124.00 for 250 mg (https://www.sigmaaldrich.com/catalog/product/sigma/10931?lang
=en&region =US).
The background information and effects of the phytocannabinoids as anti-cancer
agents is already well established (Mechoulam & Shabat, 1999), but there are still key
unresolved questions and avenues to explore for the endocannabinoids (as will be
explored later in Chapter II). Due to this, the synthesis of 2-arachidonoyl glycerol was
selected as a research goal. It seemed highly prudent to pursue a method for synthesizing
2-arachidonyl glycerol as opposed to purchasing it directly from a manufacturer, given
the price of arachidonic acid discussed previously. Moreover, and of primary interest, is
the potential to modify 2-arachidonoyl glycerol in a variety of ways, from fatty acid chain
modification or substitution, to glyceride addition, extension, or modification aimed at
increasing overall efficacy of the modified compound, either directly or through a greater
combined effect. Direct synthesis also affords the ability to generate 2-AG in a protected
form, whereupon chemical de-protection or activation can generate 2-AG on demand,
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ameliorating certain issues regarding compound availability and stability (see Chapter II
for more information).
Development of a synthetic method for production of 2-AG was sought for the
aforementioned reasons. The core goal of the research was to develop a methodology at
least as effective as previous methods in synthesizing 2-AG, with the hope of improving
yield while concomitantly investigating permutations of 2-AG for use in activity assays.

CHAPTER II
LITERATURE REVIEW
Overview
The literature review will establish important background information concerning
the endocannabinoid signaling system (ECS). By looking more closely at this receptor
system, it will be established how individual activation of each receptor in this system is
directly linked to the anti-cancer activity of cannabinoid challenge, the relevant research
data on binding of cannabinoids to these receptors, discussion of relevant structure
activity relationship data for cannabinoids of interest for these receptors, and other
pertinent information concerning endocannabinoids interacting with this receptor system.
Next, relevant physiological and chemical data for 2-AG will be established, followed by
a review of previous synthetic methodology for 2-AG culminating in the introduction of
the synthetic methodology that will be used for this research.
The Endocannabinoid Signaling System
The ECS formally consists of the two cannabinoid receptors, CB1 and CB2, their
endogenous ligands (the endocannabinoids), and the enzymes that catalyze the formation
and subsequent degradation of the endocannabinoids themselves (Wang & Ueda, 2009).
The cannabinoid receptors are of the class known as G-protein coupled receptors
(GPCRs), a family of receptors widely expressed in the body and involved in a variety of
signaling pathways, mainly sensory perception (predominantly vision, taste, and smell)
(Sugiura, Kishimoto, Oka, & Gokoh, 2006). GPCRs are composed of seven-member
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alpha-helices that are interwoven in the plasma membrane and covalently linked to a
heterotrimeric G protein located on the cytosolic side of the cellular membrane. The G
protein subunits consist of three members, designated alpha (α), beta (β), and gamma (γ).
The alpha subunit (Gα), which itself is a GTPase, has a bound GDP when no ligand or
stimulus is present and constitutes the inactive form. When a ligand or stimulus hits the
extracellular portion of the receptor, knock-on effects produce a conformational change
in the binding pocket, causing GDP to be displaced and exchanged for GTP. This
effectively activates the alpha subunit, which dissociates from the beta and gamma
subunits and migrates laterally through the cellular membrane to reach and affect its
target. The subunit's target varies based upon the type of Gα subunit and the location of
the receptor itself (Miesfield & McEvoy, 2017). The cannabinoid receptors possess alpha
subunits of the inhibitory type (Gαi/o), which inhibit adenylate cyclase to impede the
downstream signaling affected by the synthesis of the secondary messenger cAMP by the
aforementioned enzyme. Additionally, both CB receptors are positively coupled to
mitogen activated protein kinase (MAPK) signaling pathways (Howlett et al., 2002).
Another effect of cannabinoid challenge at the CB receptors, and one of primary
interest for the purpose of this research, is the de novo synthesis of ceramide as initially
reported by Guzman and colleagues (Galve-Roperh et al., 2000). Ceramide (Figure 7),
which is comprised of a sphingosine backbone with a fatty acid linked to the amine at
C-2, is the biosynthetic precursor to the class of integral plasma membrane components
known as sphingolipids, which are composed of ceramide with a C-1 linked polar head
group. The identity of the polar head group attached to ceramide specifies the type of
sphingolipid. In the case where the attached group is phosphorylcholine (-PO3CH-
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+
2CH2N (CH3)3),

the sphingolipid is designated sphingomyelin, which is a major

component of neural cell membranes (abundantly represented in the myelin sheath). As a
membrane component, sphingomyelin has little to no bioactivity, but this is not the case
with ceramide, which has been demonstrated to be integral in signaling pathways
connected to cell survival and apoptosis (Green, 2000).

Figure 7. Generalized structure of ceramide.

One of the primary means by which ceramide is generated in the cell is through
the hydrolysis of sphingomyelin via sphingomyelinase into phosphorylcholine and
ceramide. This activity has been demonstrated to be linked with CB1 activation in
primary astrocytes and C6 glioma cells through functional coupling of the CB1 receptor
with the factor associated with neutral sphingomyelinase action (FAN) (Guzman, GalveRoperh, & Sanchez, 2001). This enzyme-catalyzed generation of ceramide mediated
through FAN occurs within minutes of cannabinoid challenge. Additionally, a second
wave of ceramide generation occurs with prolonged cannabinoid challenge, beginning 72
hours after treatment and peaking after 118 hours and was "closely related to the
apoptotic death of glioma cells" (Galve-Roperh et al., 2000). This second wave of
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ceramide production was determined to be generated through de novo synthesis of
ceramide mediated by the enzyme pathway beginning with, and rate-limited by, serine
palmitoyltransferase (SPT). This mechanism was determined through measurement of
ceramide generation in the second peak time frame coupled to apoptosis of C6 glioma
when treating the cells with THC in the presence of known inhibitors for
sphingomyelinase and SPT. The results of this study indicated that the second wave of
ceramide synthesis was generated by the de novo pathway mediated by SPT.
Furthermore, the authors indicated that this activity was preserved using CB2 selective
agonists in treating human leukemia cells via p38-MAPK activation and subsequently
published those results (Herrera, Carracedo, Diez-Zaera, Guzman, & Velasco, 2005). The
key take-away from this line of research is that both CB receptors are linked into
signaling cascades that activate pro-apoptotic effects through de novo ceramide
generation. This mode of action for the growth inhibition and apoptosis of a variety of
cancer lines has been demonstrated across multiple independent studies, although not for
both receptors in every case (Table 1).
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Table 1
Pro-apoptotic Effect of Cannabinoids on Different Cancer Lines. (Adapted from Velasco
et al., 2012).
Cancer cell
CB
Ceramide Apoptosis Reference
receptor synthesis
Glioma
1 and 2
X
X
Salazar et al. (2009)
Pancreatic
2
X
X
Salazar et al. (2009),
Carracedo et al. (2006)
Hepatocellular carcinoma
2
X
X
Vara et al. (2011)
Breast
2
ND
X
Caffarel et al. (2010)
Rhabdomyo-sarcoma
1
ND
X
Oesch et al. (2009)
Mantle Cell lymphoma
1 and 2
X
X
Gustafsson et al. (2006)
Prostate
2
X
X
Mimeault et al. (2003),
Olea-Herrero et al.
(2009)
Leukemia
2
X
X
Herrera et al. (2006),
McKallip et al. (2002),
Jia et al. (2006)
Melanoma
2
ND
X
Blazquez et al. (2006)
Lung carcinoma
ND
ND
X
Preet et al. (2008)
X = confirmed present; ND = not determined

Furthermore, several lines of evidence indicate that cannabinoid challenge is
linked with an increase in endoplasmic reticulum (ER) stress, mediated through p8
(NUPR1), a transcriptional regulator that affects downstream targets critical to cell
survival, such as the Akt signaling pathway (Velasco et al., 2012). The stress response
itself is complex and most adequately understood through the processes encompassing
the unfolded protein response (UPR) of the ER. These processes are upregulated in
response to cellular stressors, such as Ca2+ depletion, oxidative injury, viral infections,
high-fat diets, hypoglycemia, the nutritional status of the cell, and certain anti-cancer
agents (Schrӧder & Kaufman, 2005). Simply put, when the workload of the ER is
outpaced by demand, the UPR is activated to either restore balance by increasing protein-
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folding capacity and destruction of unfolded/misfolded proteins, or if the stress cannot be
controlled or abrogated, then Bcl-2 mediated pathways can lead to apoptosis. This is
significant because the cannabinoid-mediated destruction of cancer cells is intimately
linked with stress induced autophagy. The p8 mediated pathway ultimately leads to
inhibition of the pro-survival kinase Akt (protein kinase B, also called the PKB pathway),
which in turn inhibits the mechanistic target of rapamycin complex 1 (mTOR1), which
then stimulates apoptosis via autophagy. Autophagy is upstream of programmed cell
death; blocking autophagy prevents cannabinoid-induced apoptosis, but not the reverse
(Salazar et al., 2009; Vara et al., 2011).
Cannabinoids also possess general anti-proliferative and anti-metastatic effects
due to inhibition of the vascular endothelial growth factor (VEGF) pathway in addition to
modulation of vital metalloproteases and associated inhibitory factors that are crucial for
adhesion and invasion of transformed cells (Velasco et al., 2012). In aggregate, these
experimental observations highlight an important feature of cannabinoids, noted
previously, that makes their study highly intriguing but also vexing; they have a plethora
of cellular targets, not limited to the CB receptors and not all of them pertinent or specific
to all cannabinoids. A prime example is that of anandamide, which has been
demonstrated to be a partial-to-full agonist of the transient receptor potential cation
channel subfamily V member 1 (TRPV1), a "nonselective cation channel that integrates
multiple noxious stimuli and is associated with the pathophysiology of various major
diseases" (Ross, 2003). In simpler terms, TRPV1 is the neurological receptor that
mediates the effects of capsaicin, the component in chili peppers that gives them their
characteristic properties of being irritating and "hot.” 2-Arachidonoyl glycerol has no
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activity at this receptor, nor do any other cannabinoids. It is this reality that makes trying
to assign activities specifically to CB receptor activation sometimes confounding but
obviously crucial when attempting to parse effects due to stimulation of the ECS.
Similar to all other GPCRs, the specific tissue location of the cannabinoid
receptor dictates the ultimate physiological function(s) of its activation. Cannabinoid
receptor distribution occurs in two primary systems: the central nervous system (CNS)
and in immune tissues (Table 2). The first of the discovered cannabinoid receptors, CB1,
was found to be widely distributed in the central nervous system (hence its previous
designation as the "central" receptor) with the highest densities occurring in the cortex,
hippocampus, basal ganglia, and cerebellum, in addition to cervical ganglia and
peripheral autonomic nerve fibers, such as those in the bladder, heart, and vas deferens
(Di Marzo, 1998). CB1 is also sparingly distributed in the hypothalamus and spinal cord
and is mostly absent in the respiratory centers of the brainstem. The distribution of CB1
is noteworthy in the sense that, being presumed as the primary mediator of
psychoactivity, the locations where the receptor is localized correlate with known
physiological effects of smoking marijuana, and the absence of receptors in the
respiratory centers may explain, in part at least, why THC and other cannabinoids have a
low lethality (Thompson, Rosenkrantz, Schaeppi, & Braude, 1973). Curiously, although
CB1 was initially found to be exclusive to the central nervous system, receptor transcripts
for CB1 have been found to be expressed in immune tissue (specifically the spleen) at a
magnitude approximately 100-fold less than CB2 (Schatz, Lee, Condie, & Kaminski,
1997), making the initial hypothesis of a neat divide between the two receptors' domains
murky. Across studies measuring overall receptor density, CB1 is typically found to be
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greater than 1 pmol/mg of tissue, making it the most abundantly expressed GPCR in
neuronal tissue and placing it on the same level as common ionotropic receptors. The
specific localization of the receptor varies between broad, uniform expression, such as in
the cerebellum, but in most neurons expression of CB1 is exclusive to synapses,
specifically the pre-synaptic terminals (Howlett et al., 2002). In addition to previously
mentioned shared downstream targets of CB1 activation (namely adenylate cyclase and
MAPK), cannabinoid stimulation of CB1 also affects various ion channels, through Gαi/o
interactions, leading to activation of A-type and inwardly rectifying potassium channels
and inhibition of N-type and P/Q-type calcium channels (Howlett, 2005).
Table 2
Cannabinoid Receptor General Information. (Adapted from Howlett et al., 2002).
CB1
CB2
Amino acids
472 (Human)
360 (Human)
Expression
CNS, peripheral autonomic Immune tissues (spleen,
neurons, sparingly located
tonsils, lymphocytes),
outside CNS
expression in CNS in
neuroinflammatory disease
2-AG Ki range
58.3 - 472 nM
145 - 1400 nM
Anandamide Ki range
61 - 543 nM
371 - 1940 nM
Primary activity
Neuromodulation, neural
Immunomodulation
network development

The distribution, overall density, and activity of the CB1 receptor hints at one of
its primary physiological purposes, namely attenuation or modulation of
neurotransmission (Bisogno et al., 2003). Neurotransmitter binding onto a post-synaptic
receptor generates a response, either through ion channel opening creating a transient
imbalance in the normal ionic content of the terminal axon or stimulation of secondary
messenger production. This stimulates the transient production and release of
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endocannabinoids into the synaptic cleft where they act as retrograde messengers and
complex with CB1 resulting in the inhibition of voltage-gated Ca2+ ion channels and
subsequent termination of neurotransmitter release (Figure 8). Via neuroblastoma
cultures treated with ionomycin, it has been demonstrated that endocannabinoid release is
specifically linked to calcium influx, and the stimulation of calcium-dependent lipases
(Bisogno et al., 1997); however, calcium independent synthetic routes mediated via
protein kinase C and A (both in the presence and absence of thrombin) have also been
elucidated in conjunction with sensory neuronal pathways (Vellani et al., 2008),
demonstrating that transient neuronal endocannabinoid synthesis can be triggered by a
number of different means.

Figure 8. Diagram of endocannabinoid release in neurotransmission.
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CB1 receptors are also implicated in proper neuronal network development during
brain growth, and research has shown that diacyl glycerol lipase (a key enzyme in the
synthesis of 2-AG) expression is required for proper axonal growth and development and
correlates strongly with shifts in receptor expression from brain development in children
to expression of the receptor as a signal modulator in adulthood (Bisogno et al., 2003). As
has been discussed previously, the receptor is hypothesized to primarily mediate the
psychotropic activity of recreational use of cannabinoids and as such is implicated in the
regulation of cognition, memory, and motor activity as well (Sugiura et al., 2006).
CB2 receptor expression occurs almost exclusively in immune tissues, with the
first identification of the CB2 receptor occurring in mouse spleen cells (Kaminski, Abood,
Kessler, Martin, & Shatz, 1992). Autoradiographic studies have identified CB2 receptor
expression in multiple lymphoid organs. mRNA for CB2 is found in the spleen, thymus,
tonsils, bone marrow, pancreas, splenic macrophage/monocyte preparations, mast cells,
peripheral blood leukocytes, and in a variety of cultured immune cells, in addition to the
prevalence in hematopoietic lineages including myeloid, macrophage, mast, B-lymphoid,
T-lymphoid, and erythroid cells. The density of the receptor in spleen and tonsils is on
the same order as that of CB1 expression in the central nervous tissues (on the order of 1
pmol/mg), but expression in human blood cell populations is tiered, following the order:
B lymphocytes > natural killer (NK) cells >> monocytes > polymorphonuclear
neutrophils > T8(cytotoxic) lymphocytes > T4(helper) lymphocytes (Howlett, 2005).
Receptor location/concentration within these various organs, tissues, and cells is not
uniform, and the exact location within each is informative of activity but is beyond the
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scope of this research to dissect further. CB2 is the primary mediator of the
immunomodulatory effects of cannabinoid use and, owing to the complex and integrated
nature of the immune response in general, a clear picture of the receptor's role in
immunomodulation is a slowly emerging reality. For instance, CB2 activity is achieved
via the same general pathways as CB1, i.e., through the Gαi/o inhibition of adenylate
cyclase and stimulation of MAPKs; however, MAPK stimulation via CB2 is complicated
by the data that, in general, endocannabinoids stimulate MAPK activity (2-AG to the full
extent, anandamide partially), but cannibinol, a phytocannabinoid derivative of
cannabidiol (CBD), one of the primary components of C. sativa, actually inhibits the
ERK family of MAPKs (Paralaro, Massi, Rubino, & Monti, 2002). The specifics of how
cannabinoids affect immune function quickly becomes difficult to parse, except for those
with an intimate working knowledge of the immune system and could account for
hundreds of pages of content in its own right. For the sake of comprehension, the primary
effects of CB2 receptor activation can be rudimentarily generalized as follows.
First, the overall effect of CB2 receptor activation seems to be the positive
regulation of immune function via the cAMP signaling cascade, although this is muddled
somewhat by the fact that CB1 receptor expression does occur within immune tissues, to
an extent 10-100 times less than CB2 receptor expression, and CB1 has been
demonstrated to be dually linked, in some cases, to both inhibitory and stimulatory Gα
subunits (Parolaro et al., 2002). This activity needs to be taken into account when
drawing a formal picture of cannabinoid effect on immunomodulation and is further
complicated by the Gα/io-dependent and Gα/io-independent stimulation of MAPKs and the
duplicitous nature of specific cannabinoids to inhibit or stimulate those signaling
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pathways. Regardless of the complicating factors, a generalization that can be made is
that cannabinoid challenge has the effect of antagonizing immune cell activation,
especially in the early stages of such activity. For instance, anandamide generally inhibits
T and B cell proliferation, as does 2-AG, but inhibition by 2-AG appears to be critically
dependent on overall cell density, which was attributed to a possible positive effect
achieved through the generation of a 2-AG metabolite with immunostimulatory effects
occurring as a result of increased metabolism at the higher cell density (Parolaro et al.,
2002). In addition, THC treatment of murine specimens has been demonstrated to cause
direct changes in immunological profile and induce mobilization of myeloid-derived
suppressor cells, which typically function in chronic inflammatory conditions,
particularly those that derive from neoplastic disorders (Mantovani, 2010). Selective
activation of the CB2 receptors has also been demonstrated to induce apoptosis of an
array of different immune cell types, which has been proposed to be involved in the
immunosuppressive effects of cannabinoid challenge (Parolaro et al., 2002). Given these
data, it seems that cannabinoid challenge at CB2 could be stimulatory for tumor growth
(and it is indeed implicated as being a culprit for that effect); however, in certain cancer
types (pancreatic, breast, and hepatic) CB2 antagonists abrogate the anti-cancer effect of
cannabinoid treatment, which seems to contradict the evidence that CB2 activation is
probably harmful to the natural anti-cancer function of the immune system (Velasco et
al., 2012). Taken in aggregate, the data surrounding the effects of CB2 receptor activation
on immune function indicate that receptor activation leads ultimately to immune
suppression in general, but there is also strong evidence that cannabinoid challenge elicits
unique effects on transformed (cancerous) vs non-transformed cells (Velasco et al.,
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2012). The paradigm of immune suppression linked to CB2 activity is one that is under
active investigation and continuous refinement, and it is vital to keep the unique
peculiarities associated with the structurally, and in some cases functionally, diverse
cannabinoids in mind when assessing studies concerning this topic.
Both CB receptors are generally found on average to be upregulated in cancerous
tissue compared to non-cancerous tissue (see Table 3), the exact pathway by which this
occurs being currently unknown. One interpretation of the correlation between receptor
upregulation and malignancy might be an increased need or benefit for ECS signaling for
uncontrolled growth, which is not exhaustive of the possibilities, but if true it might
explain, at least in part, data that indicate activity at CB receptors is pro-tumorogenic.
Conversely, there are data that link receptor knockout and increased expression of
degradation enzymes of the ECS pathway (explored further later), to the development
and progression of aggressive cancer types (Velasco et al., 2012). Fundamentally, this
means that utilizing the ECS could result in either one of two outcomes when treating
cancer cell populations. Either positive outcomes could occur, in this case, positive being
cell cycle arrest or cell death, or negative, meaning accelerated growth compared to
control or no effect. There is already a significant data pool that pairs the ECS with protumorogenic (negative) and anti-tumorogenic (positive) outcomes depending on different
experimental conditions, primarily the specific cancer cell being studied, the
cannabinoids being assayed, and the concentration of the cannabinoid in the experimental
assays or growth conditions (Velasco et al., 2012). The Flygare and Sander (2008) article
serves as an excellent introductory resource to this growing body of work (see Table 1).
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Table 3
CB Receptor Upregulation in Different Cancer Types. (Adapted from Flygare and
Sander, 2008).
Cancer sub-type
CB1
CB2
Astroglia
+
=
Breast
++
Mantle cell lymphoma
++
++
Acute myeloid leukemia
N/A
++
Hepatocellular carcinoma
++
++
Non-melanoma skin cancer
=
=
Prostate
++
++
(-) partially downregulated, (=) no change, (+) partially upregulated, (++) upregulated

Determining the impact of different cannabinoids at CB receptors across different
cancer cell types has been straightforward; however, determining the effect of
cannabinoid concentration, specifically for 2-AG and other endocannabinoids, has not.
The first issue, which will be expounded upon later, is the inherent labile nature of the
ester moiety in 2-AG. Whether through hydrolysis or isomerization into the 1 or 3
position, the affinity for the receptor can be affected, if not abrogated, by these natural
chemical transformations. In general, the highly lipophilic nature of most cannabinoids
complicates all in vitro studies of affinity assays for receptor binding, given that the CB
receptors are membrane bound and thus most assays must address the issue of membrane
intercalation as a complicating factor in accurately assaying cannabinoid concentrations
in solution across the time necessary to perform the assay.
The high variability across various studies measuring CB receptor affinity for 2AG and other endocannabinoids reflects these issues. Table 2 presents Ki values, or rather
a range of values, referenced from Howlett et al. (2002). The range is indicative of
minima and maxima derived from various studies included in that reference. The data
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speak for themselves; however, it is prudent to add a few pertinent background details to
flesh out the quantitative data. In general, the literature surrounding binding assays for 2AG and anandamide indicate that anandamide is in fact a partial agonist for both CB1 and
CB2 whereas 2-AG is a full agonist (Sugiura, Kobayashi, Oka, & Waku, 2002). This is a
curious discovery, and one of the reasons 2-AG was selected for synthesis over
anandamide for the current research. Anecdotally, when reviewing the literature, the
general trend reported by researchers is that anandamide has a higher affinity for both CB
receptors compared to 2-AG, however, looking at the range of binding affinity values in
aggregate data (see Table 2), this claim is not supported. Most likely, sensitivity of assays
to experimental conditions and the difficulties associated with assaying these compounds
not addressed by some experimental methodologies is contributing to the disparity
between some researchers claims and the breadth of available data. A prime example of
this is a study measuring the binding affinity of 2-AG and anandamide at CB1 by
Gonsiorek et al. (2000). When measuring the Ki of 2-AG and the Ki of anandamide
against CP-55,940 (Figure 2), the reported Ki values were 949 ± 270 nM and 795 ± 46
nM, respectively, whereas EC50 values were 38.9 ± 3.1 nM and 121 ± 29 nM,
respectively, from the same experimental conditions (Gonsiorek et al., 2000). The results
demonstrate clearly that 2-AG is a more potent activator of CB1 but has a lower affinity
compared to anandamide, confusingly however, the authors claimed that both 2-AG and
anandamide were full agonists at CB2, which runs directly counter to the consistent
message of numerous publications from both Mechoulam and Sugiura that anandamide is
only a partial agonist. For example, one of the first studies published concerning the
agonist status of 2-AG at CB1 by Sugiura indicated that a response (increase in
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intracellular Ca2+) was detected from 2-AG administration at a concentration as low as
0.3 nM, in line with potent CB1 selective agonists, such as CP-55,940, whereas
anandamide did not elicit a full response at any concentration (Sugiura et al., 1999). The
disparity in results reported from multiple labs across various studies highlights the need
for refined and continued studies of receptor interactions, at least if a highly accurate
measure of CB receptor affinity for their natural ligands is desired.
A helpful development for assessing CB receptor-ligand interactions is the
elucidation of the crystal structure of CB1, which was recently reported (Hua et al., 2016).
The receptor was crystallized as a complex with AM6538 (Figure 9), a rimonabant
derivative synthesized specifically for the crystallization study with high affinity for the
receptor.

Figure 9. AM6538.

Additionally, to facilitate crystallization of the receptor-ligand complex,
truncation of the CB1 receptor was required, which bears keeping in mind prior to
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extrapolating on pertinent binding pocket elements. To facilitate discussion, it is prudent
to parse AM6538 into three basic "arms" (Figure 10). From the pyrazole ring core, the
arms essentially designate the three different binding pockets of CB1. The 2,4dichlorophenyl ring constitutes arm 1, the 4-aliphatic chain substituted phenyl ring
constitutes arm 2, and the piperidin-1-ylcarbamoyl group constitutes arm 3.

Figure 10. AM6538 "arms".

It is somewhat difficult to look at AM6538 and mentally superimpose how the
natural ligands 2-AG and anandamide interact with the pockets outlined by the arms of
this compound. As an inverse agonist AM6538 binds CB1 in an inactive state, but the
study authors were able to use molecular modeling software to predict how a suite of
agonists most likely interacts with the binding pocket. Giving the simplest distillation, the
hydrophilic head of each endocannabinoid sandwiches itself into the pocket occupying
the space of the pyrazole core and the shallow pocket of arm 3, formed by the N-terminal
portion of the receptor and extracellular loop 2, while the aliphatic tail of the arachidonic
acid folds itself into a similar "C" shape as that in Figure 4 and sequesters itself into the
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deep pocket of arm 2. Arm 1 is predominantly involved in antagonist binding and so has
little to no interaction in agonist binding models (Hua et al., 2016).
Structure Activity Relationship (SAR) data on anandamide shows that
substitution of the hydroxyl head of the ethanolamide group with chlorine or fluorine
sharply increases CB1 selectivity, by approximately 10 fold, whereas introduction of
variation into the N-alkyl group also caused impressive gains in selectivity of a similar
magnitude in Ki for CB1 when looking at substitution of the N-ethyl group for isopropyl
or n-propyl, demonstrating that it is possible to modify the endogenous ligands for
increased selectivity (Mechoulam et al., 1998). To date, no crystallographic studies have
successfully isolated CB2, but expansive SAR studies with selective agonists have helped
to fill in a rough picture of the binding pocket (unfortunately SARs for 2-AG interactions
with CB receptors are scarce, but anandamide structural requirements can be loosely
translated to 2-AG in some cases). These studies are providing critical insight into
receptor-ligand interactions for the CB receptor class, especially as the understanding of
nascent putative CB receptors has grown with time (Pertwee et al., 2010).
The entirety of the preceding data demonstrates that cannabinoids in general
represent compounds of interest for research, given their physiological effects on cancer
cells, and establishes that there are good reasons for pursuing synthesis of
endocannabinoids, specifically 2-AG, given the absence of accurate data for receptor
interactions and the relative absence of information on this endocannabinoid compared to
other endocannabinoids. More specific background information on 2-AG, the
endocannabinoid of focus for this research, will now be discussed.
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2-Arachidonoyl Glycerol Biosynthesis
and Degradation
The biosynthesis of endocannabinoids following a stimulus occurs through
different enzymes and intermediates depending on the endocannabinoid in question.
Because the nature of the current thesis research is concerned with the chemical synthesis
of 2-AG, the remainder of this chapter will focus exclusively on this endocannabinoid,
although there are many generalizations and commonalities between the pathways for the
synthesis of 2-AG and anandamide, one obviously being the dependence on arachidonic
acid containing intermediates (Mechoulam et al., 1998). Figure 11 gives a template that
will be used in describing the various ways that 2-arachidonoyl glycerol can be
biosynthesized from a variety of precursors. Taking tissue measurements of 2-AG can be
complicated by the collection methods employed. In the case of decapitation of murine
specimens to measure tissue concentrations, 2-AG levels swell to 15 times their normal
tissue concentration, normal tissue concentration being determined from flash freezing
whole mice specimens prior to preparing tissue samples for analysis. Variation in tissue
concentrations of 2-AG between sub-compartments of rat and mice brains are within 1.0
to 10 nmol/g of tissue concentrations, which are roughly correlated with reported human
values which tend to be an order of magnitude less (Sugiura et al., 2006). As will be
discussed further, free 2-AG will be short lived in a physiological environment, but even
more fundamentally, "free" 2-AG might be something of a misnomer.
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Figure 11. Biosynthetic routes for 2-AG from various precursors.
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2-AG is one of the more abundant monacylglycerols in the brain. Most 2-AG is
produced from the hydrolysis of diacylglycerols (DAGs) containing arachidonic acid in
the 2 position by an sn-1 selective DAG lipase (step G in Figure 11). Pre-cursors for
DAGs come from phosphoinositides (PI) that are cleaved of their phosphate moiety by
PI-selective phospholipase C (step E in Figure 11) or through the activity of a similar
enzyme on phosphatidic acid (step F in Figure 11). Step C depicts the activity of
phospholipase A1 converting a phosphoinositide to a lysophospholipid, and then in step D
(or A) subsequent conversion of the phospholipid to 2-AG via lysophospholipase C. Step
B demonstrates the possibility of production of 2-AG from a triglyceride precursor,
which would be a less immediate source (Bisogno, Ligresti, & Di Marzo, 2005). Path G
is the "on-demand" pathway for 2-AG synthesis.
The lipopathic nature of the cannabinoids suggested potentially that their
diffusion into the synapse was passive in nature, however, rapid removal from the
intracellular space (whether expulsion or re-uptake and inactivation) is a necessary
feature of a receptor-mediated process and suggested some transporter. Evidence for this
transporter was first produced in studies examining anandamide cellular uptake and the
fact that it was a saturable, temperature-dependent, and inhibitable process (Di Marzo et
al., 1994). The proposed transporter was named anandamide membrane transporter
(AMT) and was shown to potentially facilitate transport of 2-AG, along with a small host
of additional cannabinoids (Bisogno et al., 2005). Inactivation of 2-AG is achieved
primarily via two enzymes. The enzyme fatty acid amide hydrolase (FAAH) can cleave
2-AG to arachidonic acid and glycerol (the two primary components from enzymatic
hydrolysis) but is weakly effective towards this endocannabionid and ablation does not
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lead to an increase in 2-AG concentration like it does anandamide. Rather,
monoacylglycerol lipase (MAGL) in either membrane-bound or soluble form, is
primarily responsible for cleaving 2-AG to arachidonic acid and glycerol and is strongly
associated with CB1 receptor localization (Bisogno et al., 2005).
One of the peculiar aspects about hydrolysis of the endocannabinoids is the
liberation of arachidonic acid, which is a polyunsaturated fatty acid that serves as the
precursor to eicosanoids, a diverse array of biologically active compounds broadly
involved in pain and inflammation. The full scope of effects from the localized increase
in concentration of this fatty acid have not been fully explored, however, localized
arachidonic acid concentrations have been shown to be capable of mediating Ca2+
stimulated transients, perhaps further feeding into the primary function of the compound
in its monoglycerol state (Damron, Wagoner, Moravec, & Bond, 1993). The production
of this physiologically diverse precursor is an effect that must be considered when
drawing comparisons between relevant CB agonists, since most synthetic and plant-based
cannabinoids are not metabolized using the same enzymes of the ECS system but rather
utilize common metabolic enzymes, such as the cytochrome P450 family, to be converted
into biologically inactive forms and excreted. This is one of the primary reasons that
exploring the activity of endocannabionids is of interest, as their unique integration with
existing biological "circuits" may confer to them unique capacities that would otherwise
be absent, especially when looking at exposure of CB receptors to endocannabinoids in
disease states where inflammatory and nociceptive processes are occurring.

33
2-Arachidonoyl Glycerol Stability
As noted previously, the stability of 2-AG in aqueous solutions is subject to many
factors. Specifically, three key processes, highlighted in Figure 12, contribute to the
progressive and nearly complete conversion or loss of 2-AG, irrespective of enzymatic
action. Rouzer and colleagues published an experimental assessment of 2-AG stability
looking at various pertinent parameters for experimental assays or other procedures and
noted important upper limits for time-based procedures, as well as other important
considerations (Rouzer, Ghebreselasie, & Marnett, 2002). In the case of oxidation and
ester hydrolysis, the authors noted that only experiments "exceeding 4 hours" would be
problematic for loss of function due to natural sample loss. However, acyl migration
could occur at rates that "would be significant in the context of experimental protocols of
an hour or less." Further elaboration of what was meant concerning this revealed that
migration of the acyl chain to the first or third position on the glycerol molecule is a
thermodynamically favored migration, and so at equilibrium the 1(3)-monoglycerol will
constitute 89 to 95% of the monoglycerol present (Rouzer et al., 2002). The speed of this
process was critically dependent on the presence or absence of serum. In the presence of
serum, the half-life for the conversion of 2-AG to 1(3)-AG was approximately 2.3 min,
and in the absence of serum the same reaction half-life was 10 min. Study authors
postulated that this might be due to the presence of albumin in serum and verified that
albumin binding was responsible for the increased rate in conversion. The consequences
of these data for developing experimental methods is obvious, as is the implication in
potentially using the compound in formulations. One further finding that was perplexing
was the steady loss of 2-AG due to processes unknown. It was determined that 2-AG will
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actually bind non-selectively to glass surfaces, and natural loss to glass containers (on the
order of 10% of total sample lost per hour) was to be expected (Rouzer et al., 2002).

Figure 12. 2-AG physiological transformations.

The pertinent results from Rouzer et al. (2002) are summarized in Table 4. These
instabilities in 2-AG in a natural cellular environment are major contributors in the dearth
of consensus in the published information concerning this compound, therefore,
developing knowledge of the chemical susceptibility of 2-AG will greatly help to inform
the discussion concerning synthetic strategy moving forward.
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Table 4
Sources of 2-AG Loss. (Adapted from Rouzer et al., 2002).
Source/condition
Oxidation
Hydrolysis
Acyl migration

Loss to glass/plastic
surface adsorption

Measure of loss
Stable up to 6 hrs at 37 °C
Stable up to 6 hrs at 37 °C
In buffer (pH 7.4): t1/2 = 10 min
In buffer (pH 7.4) with 10% FBS: t1/2 = 2 min
Base catalyzed (kcat = 78,000 M/min)
Approximately 10% loss/hr

Synthetic Pathway Proposal and Review of
Previous Methodology
Previous publications concerning 2-AG synthesis are fairly sparse. Han and
Razdan (1999) employed the Corey method for forming silyl ethers, using
triisopropylsilyl chloride to protect glycerol. The authors esterified their protected
glycerol to an activated arachidonic acid using 4-dimethylaminopyridine (DMAP), 1-(3dimethyl-aminopropyl)-3ethylcarbodiimide hydrochloride (EDCI), and dichloromethane
at ambient temperature. Subsequent deprotection was achieved using a modified tertbutylammonium fluoride (TBAF) process employing an acetate buffer kept at -20 °C over
night. The reported yield for 2-AG was 59%. The need to bring reaction conditions to
lower overall temperatures is a common theme reported in publications. For instance, the
method employed by Suhara and colleagues sought to create a 1,3-dioxane ether complex
through glycerol that could be selectively cleaved to form the 2-monoglycerol on
demand. The methodology was inspiring, and the yield was improved, but still
underwhelming, peaking at 69% (Suhara et al., 2000). A more recent publication from
Cartoni et al. (2004) critiqued what was seen as the established sensible synthetic route
(Figure 13). The appeal of their method comes from having pared the number of
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individual synthetic steps down to two, by addition of a pre-protected glycerol in the
form of 1,3-dibenzyloxy-2-propanol, and then subsequently deprotecting. The
deprotection was screened with various reaction conditions, but the best method only
yielded a 70% recovery (with returns as low as 30%) after deprotection (Cartoni,
Margonelli, Angelini, Finazzi-Agro, & Maccarrone, 2004). Given these outcomes, older
methodologies are still clearly viable, and it is from the principle scheme in Figure 13
that the synthetic route for the current research was drawn.

Figure 13. Classic synthetic scheme for 2-AG.

The Han synthetic method, which was essentially a retooling of a method
developed by E. J. Corey in 1972 (Corey and Venkateswarlu, 1972) was sound, but
impeded by issues with the chosen protecting group. Silyl ethers are susceptible to attack
by the extremely basic fluoride anion and an acetate buffer was employed, presumably, to
ameliorate formation of 1(3)-AG by keeping pH < 7. The trade-off for stabilization of the
product on the overall reaction kinetics appears to be manageable (assuming overnight in
the Han methodology does not constitute a time period over eight hours) and if the
protecting group were more, or at least as, labile, it seems that it should be possible to
tweak the deprotection conditions and return a better result. With that in mind, tertbutyldiphenylsilyl chloride was chosen to form a silyl ether protecting group for the
synthesis of 2-AG.
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Figure 14 gives a simplified outline of the proposed synthetic scheme for 2arachidonoyl glycerol for the current research. The initial proposed synthetic method
employed dihydroxyacetone (DHA) as a way to ensure protection specificity, and so
added additional steps that made the use of DHA less appealing as a starting material
once it was realized that the protecting group was specific for primary alcohols by a wide
margin in the original reaction conditions (Patschinski, Zhang, & Zipse, 2014); however,
as will be elaborated later, it was found that the doubly protected DHA could be
conveniently separated from DMF called for in the original Corey procedure. DMF is
unfortunately one of the few polar, aprotic solvents that can dissolve all the necessary
reagents for the synthetic procedure in required amounts, and efficient and clean removal
of the solvent can be a beneficial step to include if thinking of scale up.

Figure 14. Simplified synthetic scheme flow chart.
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Based upon the breadth of data discussed thus far, the reasons for pursuing this
research should be readily apparent. Cannabinoids are compounds with demonstrated
anti-cancer effects on a variety of cancer sub-types that act upon a unique class of
receptors, and there is potential in developing and building upon previous synthetic
methodologies to allow further experimentation with these compounds to fully probe
their efficacious properties and potential. 2-AG in particular is a target of imminent
interest for synthesis due to the relatively unexplored potential of the endocannabinoids
as therapeutic agents compared to the other cannabinoids, and the relatively mixed data
on the compound as a whole.

CHAPTER III
MATERIALS & METHODS
Materials
Materials were primarily acquired from Sigma-Aldrich and American Type
Culture Collection (ATCC). Reagent grade (purity ≥ 95%) dihydroxyacetone (DHA)
(D107204), tert-butyldiphenylsilyl chloride (t-BDPSCl) (190502), imidazole (I5513),
dimethyl formamide (DMF) (PHR1553), acetone (650501), acetonitrile (271004),
dichloromethane (DX0831), chloroform-d (494275), chloroform (CX1054), methanol
(34860), denatured ethanol (187380), ethanol (absolute and reagent grade) (E7023 and
362808), thionyl chloride (230464), and methyl chloroformate (M35304) were obtained
from Sigma-Aldrich. Glycerol was provided by the laboratory stock room. From ATCC,
AsPC-1 (pancreatic cells CRL-1682), U-87 MG (neuroblastoma cells HTB-14), RPMI1620 medium (30-2001), Eagle's Minimum Essential Medium (EMEM) (30-2003),
25-cm2 culturing flasks , 75-cm2 culturing flasks, 1-mL serological pipettes, 5-mL
serological pipettes, 25-mL serological pipettes, 5-mL conical centrifuge tubes, 15-mL
conical centrifuge tubes, and 25-mL conical centrifuge tubes were obtained. All other
culturing materials were kindly provided by Dr. Steve Mackessy's laboratory, including
dimethyl sulfoxide (DMSO) and fetal bovine serum (FBS) both from ATCC. EMD
Millipore TLC Silica Gel 60, F254, aluminum backed thin layer chromatography plates
(1.10557.0001) were purchased from Fisher Scientific.
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Instrumentation
A Bruker 400 MHz nuclear magnetic resonance spectrometer was utilized for
monitoring reaction success and characterization of purified product. A Nicolet iS5
infrared spectrometer with an iD5 ATR cell from Thermo Scientific was used to analyze
starting materials and products. A Shimadzu HPLC system consisting of a LC-10AD
pump, an SPD 10A UV/Vis detector, and outfitted with a Luna Omega Polar C18 column
(4.6 mm x 150 mm; silica particle size 1.6 µm) was utilized for determining purity and
monitoring protecting group removal. A Labconco lyophilizer was utilized for conversion
of DHA dimer into monomer.
Nomenclature and Abbreviations
Before moving forward, it is pertinent to take a moment to discuss annotation of
the intermediates in the synthetic scheme. From this point, the author's own personal
shorthand will take the place of formal/IUPAC names for these intermediates, and this is
primarily because these formal terms are cumbersome. Figures 15, 16, and 17 give the
structure, IUPAC name, and the author’s abbreviation for each compound. This naming
system will be maintained throughout the paper.

Figure 15. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-propanone - DHA-DS
(doubly silylated).
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Figure 16. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-hydroxypropane - G-1,3-DS.

Figure 17. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-propanoyl-(5Z, 8Z, 11Z,
14Z)-eicosatetraenoate - 2-AG-DS.

Synthetic Methodology
Step 1 - Monomerization of
Dihydroxyacetone
The overall synthesis of 2-AG was carried out on the milligram scale, but for the
purpose of conversion of DHA dimer into monomer (Figure 18) for use as a starting
material, amounts ranging from 1 to 3 grams were used. To aid in the quick recovery of
the monomer, the minimum amount of deionized (DI) water to dissolve the DHA crystals
was used in every case, which involved adding ~0.5 mL aliquots of DI water until a
concentrated solution was formed. The concentrated solution was stirred for one hour
before it was transferred into a Labconco freeze drying flask and frozen with uniform
distribution in the flask using liquid nitrogen. Then, the flask was attached to the
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Labconco lyophilizer and brought to dryness at approximately 0.050 mBar at 0 °C. Due
to the hydrophilic nature of DHA, multiple cycles of freeze drying were often required to
bring to full dryness. In some cases, it was necessary to triturate the semi-solid product
with very minute aliquots of absolute ethanol and vigorously whisk the resultant paste
until dry crystals were returned. Distributing a semi-hydrated sample onto a large watch
glass and passing nitrogen gas across the surface combined with mechanical perturbation
was also helpful in bringing a sample to complete dryness. In some cases, samples that
proved particularly difficult were placed in the fume hood over night to dry from the
laminar air flow in the hood. Successful monomerization was determined by melting
point analysis; the monomer has a melting point range of 89 - 91 °C, and the dimer melts
between 75 - 80 °C. Stored in a sealed container and placed in a desiccator, the monomer
will slowly convert to dimer over a period of several months (Davis, 1973).

Figure 18. Monomerization of DHA.

Step 2 - Protection of
Dihydroxyacetone
Figure 19 gives an overview of the first synthetic step: addition of the protecting
group. To a 25-mL round-bottom flask was added 100 mg (1.1 mmol) of monomerized
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DHA and 10 mL of DMF. A stir bar was then added, and the flask contents were mixed
gently until homogeneity. Then 151 to 226 mg (2-3 molar equivalents) of imidazole were
added, followed with 693 µL (1.1 molar equivalents) of t-BDPSiCl. The reaction stirred
for 30 min after which it was quenched with 10 mL of deionized water. The roundbottom flask was covered with aluminum foil and placed in a 0 °C freezer, causing
precipitation of the doubly silylated (protected) DHA (DHA-DS). When using less DMF,
typically ≤ 5 mL, and using the same amount of DHA, the product typically precipitates
out of solution without needing to be cooled.

Figure 19. Protection of DHA with t-BDPSiCl.

The contents of the round-bottom flask were then transferred to a Buchner funnel
and washed with 5-mL aliquots of 0 °C deionized water while simultaneously being
ground and physically manipulated with a glass stir rod. After washing approximately 3-5
times, the crystals were carefully transferred to a pre-weighed watch glass, dried at
ambient temperature, and weighed again for recovery determination. The crystals were
stored in a screw-cap vial at 4 °C until the next step. Reaction success was monitored
using infrared spectroscopy, looking specifically for the disappearance of the diagnostic
alcohol band at 3400 cm-1. Absence of this band indicated complete double protection of
the compound, which was further verified using 1H NMR.
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Step 3 - Reduction of DHA-1,3-DS
Figure 20 shows the next step in the synthesis: reduction of DHA-DS to G-1,3DS. From the product isolated and purified in step 2, 100 mg (0.18 mmol) were added to
a 50-mL round-bottom flask containing 5 mL of tert-butanol. The flask was placed in an
ice bath, and the contents were stirred gently while 8 mg (1.2 mol equivalents) of sodium
borohydride (NaBH4) dissolved in 5 mL of basic (pH > 9) t-butanol solution was added
drop wise over 15 min. The contents were stirred for an additional 105 min, and the
reaction was quenched with 1.0 M HCl to a pH of ~7, upon which the clear reaction
mixture became slightly opaque. The solution was dried at 50 °C for 30 min to remove
the t-butanol, and the mixture was back-extracted with 5-mL aliquots of chloroform three
times. The aliquots were combined and concentrated by drying at ambient temperature on
a pre-massed watch glass and to determine recovery. 1H-NMR spectra were gathered to
determine reaction success.

Figure 20. Reduction of DHA-DS to G-1,3-DS.
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Step 4 – Esterification
Figure 21 gives the outline of the next synthetic step: esterification of G-1,3-DS
with 2-AG to form 2-AG-DS. From product isolated and purified in step 3, 100 mg (0.2
mmol) was added to 5 mL of chloroform along with 12 mg (one molar equivalent) of
imidazole in a 25-mL round-bottom flask. The flask was placed in an ice bath and stirred
at a gentle rate, and 100 mg (0.3 mmol) of arachidonic acid was added. To the flask, 5
mL of chilled chloroform containing 70 µL (1.1 molar equivalents) of SOCl2 were added
to the stirred contents of the round-bottom flask slowly over 30 min. The reaction was
stirred for another 2.5 hr before being quenched with approximately 1 mL of deionized
water. The flask contents were dried at 40 °C and filtered over anhydrous magnesium
sulfate.

Figure 21. Esterification of G-1,3-DS with 2-AG utilizing SOCl2.

The gelatinous product was then reconstituted in 5 mL of pentane and washed
three times with 5 mL of pH ≈ 9-10 aqueous NaOH. The organic layer was filtered
through MgSO4 and then added to a clean 25-mL round-bottom flask. The round-bottom
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flask was fitted with a rubber septum which was ventilated via a syringe needle and
connected via another syringe needle to a nitrogen tank. The flask was flushed with
nitrogen gas for approximately 5 min. The flask was then sealed and stored at 4 °C.
During the reaction, small aliquots were removed for 1H-NMR analysis to determine
successful esterification.
Step 5 - Protecting group removal
Figure 22 gives the generalized reaction for the deprotection step of 2-AG-DS;
multiple methods were utilized in deprotection attempts. Table 5 outlines the five primary
removal methods employed. The removal conditions are amalgamations or permutations
of removal methods employed by Han and Razdan (1999), Nicolaou and Webber (1986),
and Corey's own original deprotection method utilizing tetra-n-butyl ammonium fluoride,
TBAF (Corey and Venkateswarlu, 1972).

Figure 22. Deprotection of 2-AG-DS.
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Table 5
Protecting Group Removal Conditions.
Method

Removal Agent (all in THF)

A

6 mol eq. of TBAF

B

6 mol eq. of TBAF
1 mol eq. imidazole
6 mol eq. of TBAF
3 mol eq. of AcOH
6 mol eq. of TBAF
6 mol eq. of AcOH
10:1 HF/pyridine

C
D
E

Temperature range
(°C)
0 °C

Time (hr.)

0 °C

8 hr.

0 °C

8 hr.

-20 to 0 °C

24 hr.

-20 to 0 °C

24 hr.

8 hr.

Deprotection was carried out under inert conditions; in each case reagents were
added to a 25-mL round-bottom flask sealed with a rubber septum and flushed with
nitrogen gas. Each reaction was performed with 100 mg (0.117 mmol) of 2-AG-DS, with
the additional reagents matching the molar equivalents given in Table 5, in 5 mL of THF.
The initial three removal methods, A, B, and C, were performed for 8 hr, after which 1
mL of concentrated aqueous MgCl2 was added to the flask and the flask was gently
shaken by hand for 1-2 min to precipitate any free fluoride ion. The solution was then
vacuum filtered to remove the precipitate and subsequently transferred into a clean 50mL round-bottom flask and dried under reduced pressure at 40 °C. The flask contents
were reconstituted in 5 mL of chloroform and extracted with three 5-mL aliquots of pH
9-10 aqueous NaOH. The aqueous layers were transferred to a new flask, dried again at
40 °C, and the residual product was reconstituted in CDCl3 and 1H-NMR spectra were
taken to determine identity.
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Difficulties with the initial deprotection methods prompted a change in
methodology. For removal methods D and E, reaction time was increased to 24 hr and
each method was analyzed via HPLC. For an initial eight hours, the reaction mixture was
stirred at 0 °C and sampled at 3 hr by drawing 0.5 mL of the reaction mixture into a
syringe and transferring into an Eppendorf tube, followed subsequently with
approximately 100 mg of MgCl2 to precipitate any free fluoride ion. The solution was
then filtered into a new Eppendorf tube and adjusted to a pH of approximately 3 (verified
by spotting on pH paper) with a 1.0 M NaOH solution and was stored in a -20 °C freezer
until analysis. After stirring for 8 hr at 0 °C, the reaction flask was transferred to a -20 °C
freezer for another 15 hr, to mimic the deprotection conditions upon which these methods
were modelled. After 15 hr at -20 °C, the flask was removed, and stirred at ambient
temperature for another hour before a final 0.5 mL sample was taken at 24 hr, quenched
with 100 mg MgCl2, filtered into an Eppendorf tube, and placed in a -20 °C freezer until
analysis.
Samples from D and E were analyzed in sequence for their t-BDPSiF
concentration using high performance liquid chromatography, utilizing a Phenomenex
Luna Omega Polar C18 column and a gradient solvent system starting at 30:70
water/acetonitrile, increasing to 100% acetonitrile over 10 min, holding at 100%
acetonitrile for 10 additional min, and then reverting to the original 30:70
water:acetonitrile over 5 min (Rouzer et al., 2002). Flow rate was set to 1.0 mL/min and
the UV/Vis detector was set to dual channel mode, detecting at 220 and 274 nm
simultaneously. Aliquots of samples (20 µL) at each time point from each method were
analyzed and chromatograms for each sample were collected. Deprotection success was
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determined by calculating the concentration of t-BDPSiF, the primary by-product of
deprotection which absorbs at 274 nm (Figure 23). Relevant data are discussed in Chapter
IV.

Figure 23. Production of t-BDPSiF during deprotection step.

The concentration of t-BDPSiF from each sample set was calculated from a
standard curve using t-BDPSiF generated by incubating 109 mg of t-BDPSiCl with 250
mg of TBAF in 1 mL of THF for 24 hrs. After which, the solution was quenched with
100 mg of MgCl2 and vacuum filtered. The filtrate was recovered and used as a stock to
prepare a series of increasingly dilute standard solutions which were analyzed using the
previously discussed HPLC methodology.
The concentration of t-BDPSiF recovered from deprotection in each sample
(determined from the generated standard curve) was converted into moles and then that
value was divided by the total number of moles of sample available to determine total
deprotection, which was then converted into percent deprotection (see Chapter IV for a
sample calculation).
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Cytotoxicity Assay
In anticipation of successful synthesis and isolation of 2-AG, and in the interest of
further project development, methods to screen cytotoxicity of 2-AG against various
cancer lines were investigated and developed simultaneously with synthetic method
development. At the recommendation of collaborators in the School of Biological
Sciences, the MTT assay was selected for screening drug action against cellular
proliferation (Berridge, Herst, & Tan, 2005). The MTT assay is a colorimetric assay for
measuring cellular metabolism via the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) to its insoluble formazan, (E,Z)-5-(4,5dimethylthiazol-2-yl)-1,3-diphenylformazan, catalyzed by mitochondrial NADPHdependent reductases (Figure 24).

Figure 24. Reduction of MTT to its formazan via mitochondrial reductases.

Utilizing the MTT assay, it is possible to determine proliferation of cells treated
with different cannabinoids at different concentrations versus controls by measuring the
presence of the formazan product (brought into solution with the nonionic poly-
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oxyethylene surfactant NP-40). Healthy, intact cells will metabolize MTT to formazan,
while cells that are in apoptotic or autophagic pathways (or that are simply dead) will not,
giving a simple and effective method for measuring reactivity to cannabinoid treatment
by measuring colorimetric response of the control wells and comparing to the treatment
wells. Greater absorbance of sample versus control indicates proliferation, while less
indicates death/autophagy. A sample assay protocol is given below, written specifically
for the pancreatic cancer cell line CRL-1682. The only variation in this methodology
from cell line to cell line would be the media employed.
Assay Procedure
Pancreatic cancer cells from ATCC (CRL-1682: https://www.atcc.org/
products/all/CRL-1682.aspx), an adherent cell type, were plated into a 25-cm2 Corning
culture flask with approximately 11 mL of RPMI 1640 media (https://www.atcc.org
/Products/All/30-2001.aspx) with 10% fetal bovine serum (FBS) (https://www.atcc.org
/products/all/30-2020.aspx) (subsequently referred to simply as media). Cells were
incubated for 24 hr and were subsequently trypsinized using 3 mL of a 0.25%
trypsin/0.53 mM EDTA solution (https://www.atcc.org/products/all/30-2101.aspx) and
passed into a 75-cm2 Corning culture flask with 25 mL of media. The cells were then
cultured for an additional 48 hr, with media refreshed every 24 hr, until the flask was
confluent (70 to 80% cell density). The cells were then trypsinized and counted in
triplicate using a hemacytometer, with the average of the three cell counts being used to
determine overall cell density.
Cells were then plated at the following cell density given in Table 6. The plate
was incubated for 24 hr allowing cells to settle and adhere to the wells. Finally, the wells
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were refreshed with media and the appropriate wells were treated with the cannabinoid
that was being screened. Treatment involved addition of 1 µL of a prepared stock
solution of the cannabinoid in absolute ethanol (one of the few amenable vehicles for
cannabinoids). Ethanol is a common disinfectant, owing to its ability to intercalate into
cell membranes causing lysis and subsequent death, which is why well treatment was
kept to a single microliter of cannabinoid in vehicle (Tapani, Taavitsainen, Lindros,
Vehmas, & Lehtonen, 1996) and readings were corrected in reference to control well
outcomes. The cellular stock solution concentration was varied to enable screening across
concentrations of interest and was usually in the range of 100 µM to 1 mM. Several
methods of serial dilution were available for generating treatment wells. The first
involved preparing increasingly dilute stock solutions of cannabinoid in ethanol and
treating each well directly, adding 1 µL of control and filling with 99 µL of media to
bring to a final volume of 100 µL. This method allowed for easy dilutions by a factor of
ten but was time consuming. Another method, requiring more experience handling cell
culture and multi-channel pipettes, was to refresh all the treatment wells with 100 µL of
media and then prepare treatment wells in row A at 200 µL total volume at the desired
concentration. Then, using a multi-channel pipette, 100 µL from each treatment well in
row A were transferred to the corresponding well in row B and mixed with the multichannel pipette, diluting the original stock concentration by half instead of an order of
magnitude. This process was repeated across each well (refreshing tips in between
treatments) until finished. Each plate also contained three additional categories of wells
in addition to treatment wells. First, two series of control wells plated at the same cell
density and treated with an identical amount of total ethanol content as the treatment
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wells were prepared to serve as a baseline for treatment efficacy, and absorbance from
these wells was used to correct absorbance from other treatment wells by simple
subtraction of the control absorbance from the treatment absorbance. Second, a blank
series was prepared on each plate to correct background absorbance from media and
vehicle. Finally, a series of wells plated at different cell densities were prepared on each
plate to serve as a standard curve for determining end point cell density for the treatment
wells (Table 6). After refreshing the media, the cells were incubated for 24 hr. Then, 10
uL of MTT reagent were added to each well. The cells were incubated for another 24 hr.
After this, the wells were treated with 10 µL of NP-40, placed in the dark for 4 hr, and
then absorbance in each well was read at 570 nm using a plate reader.
Table 6
Cell Density for MTT Assay (in cells/mL).
1

2

3

4

5

6

7

8

9

10

11

12

A

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

B

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

C

1000

1000

1000

1000

1000

1000

0

0

0

0

0

0

D

1000

1000

1000

1000

1000

1000

E

1000

1000

1000

1000

1000

1000

F

1000

1000

1000

1000

1000

1000

G

50000

50000

50000

50000

25000

25000

25000

25000

10000

10000

10000

10000

H

5000

5000

5000

5000

1000

1000

1000

1000

500

500

500

500

[Rows] – (Columns) – Contents; [A-F] – (1-6) – Treatment wells; [A-B] – (7-12) –
Control wells; [C] – (7-12) – Blank wells; [G-H] – (1-12) – Standard curve wells; [D-F] –
(7-12) – Empty

CHAPTER IV
RESULTS & DISCUSSION
Conversion of Dihydroxyacetone
Dimer to Monomer
Table 7 gives the percent recovery for DHA (dihydroxyacetone) dimer conversion
into monomer. The primary issue complicating the process of recovery was the tendency
for DHA to cling to glassware, and it is for this reason that conversion was carried out in
400-mL beakers as opposed to round-bottom flasks. Getting full recovery often required
meticulous scraping of glassware with a spatula and the narrow necks of round-bottom
flasks unnecessarily complicated this process. Successful conversion was determined by
melting point analysis as discussed in Chapter III.
Table 7
Percent Recovery for Conversion of DHA Dimer to DHA Monomer.
Sample Mass (g)
Recovered Mass (g) Percent Recovery Trituration (Y/N)
1.020

0.857

84.0%

Y

1.017

0.942

92.6%

Y

0.504

0.456

90.5%

Y

1.090

0.989

90.7%

Y

3.215

3.214

99.9%

N

5.045

4.884

96.8%

Y
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Silylation of Dihydroxyacetone
to Form DHA-DS
Prior to collecting 1H-NMR spectra, reaction progress and product purity were
assessed through qualitative thin layer chromatography (TLC). Several solvent systems
were tested for their usefulness in this regard. The most useful proved to be a denatured
ethanol solution (91.85% ethyl alcohol, 5% methyl alcohol, 1% ethyl acetate, 1% methyl
isobutyl ketone, 1% hydrocarbons, and 0.15% water) both for developing plates and for
dissolving starting materials and products. Spotting sample aliquots straight from the
reaction flask and detecting spots on a plate with iodine resulted in diffuse, amorphous
streaking across the silica. This was discovered to be a consequence of the DMF
interacting with the silica; the problem was resolved by diluting approximately 10-20 µL
of the aliquot from the reaction mixture in half a milliliter of denatured ethanol before
applying to the plate. This greatly improved spot resolution.
Figure 25 shows the 1H-NMR spectrum of purified crystals of DHA-DS in
CDCl3. Clearly visible in the spectrum are the signals from DMF (Figure 26), singlets at
2.980, 2.911, and 8.051 ppm (faintly visible upfield of the aromatic signals). Attempts
were made to thoroughly purify the product, as described in Chapter III, but no amount of
washing was successful in eliminating the DMF signals from any 1H-NMR spectra of the
DHA-DS samples. Application of heat to evaporate the excess DMF was not helpful
either, as DMF is potently non-volatile (boiling point of 153 °C), and product browning
occurred at temperatures above 80 °C.
Based upon the structure of DHA-DS (Figure 15), the expected 1H-NMR
spectrum should produce a singlet in the methyl region (approximately 0-1 ppm) from the
methyl groups on the protecting group, which when doubly protected should be
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equivalent, a singlet from the equivalent methylene groups adjacent to oxygen at
approximately 3-5 ppm, and signals from the aromatic hydrogens from the phenyl groups
at approximately 7-8 ppm. These signals are clearly present in Figure 25. Full double
protection was also corroborated by IR spectroscopy, specifically by monitoring for the
absence of the diagnostic alcohol band that occurs from approximately 3400 to 3600 cm-1
(Figure 27). Table 8 gives the percent recovery for reactions conducted to determine yield
for this step, along with the average recovery for these reactions and the standard
deviation among them.

Figure 25. 1H-NMR spectrum of DHA-DS in CDCl3.
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Figure 26. 1H-NMR spectrum of DMF in CDCl3.

Figure 27. IR spectrum of DHA-DS.
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Table 8
Percent Recovery of DHA-DS.
DHA-DS recovered (g)
0.604
0.625
0.599
0.587
0.668
Average

Percent Recovery
92.2%
97.0%
94.8%
92.4%
98.7%
95 ± 3%

Reduction of DHA-DS and Recovery
of G-1,3-DS
Reduction of DHA-DS to G-1,3-DS was accomplished through the well-known
reducing agent, sodium borohydride (NaBH4). The solvent for the reaction was t-butanol,
selected after searching for methods that might offer an insight into which solvent would
be best suited for using NaBH4 (Lecher, 2007). In experimenting with other solvent
systems, ethanol and chloroform were found to be suitable substitutions as well. Percent
recovery for reactions are recorded in Table 9. The reduction of the carbonyl of DHA-DS
into an alcohol changes the physical state of the product from solid to a viscous liquid.
Table 9
Percent Recovery of G-1,3-DS
Reaction Solvent
t-butanol
t-butanol
t-butanol
Chloroform
Ethanol

Percent Yield
95.7%
97.1%
91.5%
99.7%
96.8%
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Use of Glycerol as a Starting Material
As mentioned previously in Chapter II, DHA was selected as a starting material to
ensure protection specificity for the 1 and 3 positions for glycerol (after DHA-DS was
reduced with NaBH4) but this was found to not be a necessary step, as the introduction of
the silyl ether using the original protection conditions employed in the Corey procedure
were selective for primary alcohols (Patchinski et al., 2014). Step 1 (Figure 14) shows
how using glycerol as a starting material to produce G-1,3-DS circumvents the need to
monomerize and reduce DHA, which makes using glycerol as a starting material
appealing. The ease of isolation of DHA-DS from DMF was the primary reason it was
continued to be utilized as a starting material, as it was hoped that the DHA-DS crystals
would be easier to purify of residual DMF rather than the viscous and difficult to handle
liquid that G-1,3-DS is, however, further work with the synthetic method, discussed later
in this chapter, will highlight how this might not even be necessary.
For the sake of verification of this step, a stock of glycerol was acquired from the
university chemical stock room, and sample trials were conducted to produce G-1,3-DS
from glycerol. Reaction conditions were identical to those from the original procedure to
produce DHA-DS from DHA. Approximately 100 mg (1.1 mmol) of glycerol were
measured directly into a 50-mL round-bottom flask by dipping a clean spatula into the
glycerol and allowing the glycerol to drip off the spatula tip into the 50-mL round-bottom
flask resting in a 150-mL beaker, all of which were pre-tared. The glycerol was dissolved
in 5 mL of DMF, to which 225 mg (two molar equivalents) of imidazole were added. The
reaction mixture was stirred at ambient temperature and 700 µL (1.1 molar equivalents)
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of t-BDPSiCl were added. The reaction mixture was stirred for 30-60 min and then the
flask was sealed and wrapped in aluminum foil and placed in a 4 °C refrigerator.
Recovery of G-1,3-DS was difficult, but fortunately when the reaction flask was
cooled, G-1,3-DS separated from DMF, and settled as a solidified gel at the bottom of the
reaction flask. The DMF was carefully decanted from the G-1,3-DS, and the product was
scraped onto a watch glass and dried under nitrogen gas. G-1,3-DS itself is water soluble,
as attempts to purify with chilled 1 mL aliquots of deionized water demonstrated, and so
the convenient method of washing DHA-DS was not amenable with G-1,3-DS. Percent
recovery for this process was not determined, but 1H-NMR data to verify protection
success was gathered by adding approximately 10-20 mg of G-1,3-DS to 1 mL of CDCl3
and analyzing.
G-1,3-DS 1H-NMR Analysis
Figures 28 and 29 display 1H-NMR spectra of samples of G-1,3-DS isolated from
different syntheses employing the two different starting materials discussed previously.
The first (Figure 28) comes from a synthesis employing DHA-DS as a starting material,
and the last (Figure 29) comes from a synthesis utilizing glycerol as starting material.
DMF signals are identifiable in both spectra. Based upon the structure of G-1,3-DS
(Figure 16), the 1H-NMR spectrum for G-1,3-DS might be expected to be identical to that
of DHA-DS, save for the addition of two signals, a singlet and a quintet, corresponding to
the methine hydrogen and hydroxyl hydrogen now present at C-2. This is in fact, not the
case, as can be readily observed in Figures 28 and 29. The region from 3.5 to
approximately 4.0 ppm displays a more complicated splitting pattern.
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Figure 28. 1H-NMR of G-1,3-DS in CDCl3 synthesized from DHA-DS.

Figure 29. 1H-NMR of G-1,3-DS in CDCl3 synthesized from glycerol.

The reason for this splitting pattern can be explained by the spectrum in Figure
30, which is an 1H-NMR spectrum of glycerol outlined to explain the splitting pattern.
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The reduction of the carbonyl at C-2 transforms C-2 into a pro-chiral carbon, and thus the
splitting of the methylene and methine protons is influenced by the now diastereotopic
nature of the methylene protons, Ha (red) and Hb (blue) in Figure 30. The spectra of G1,3-DS in Figures 28 and 29 demonstrate this complex splitting as each hydrogen is
“seen” individually, rather than when they were equivalent. Integration for the 1H-NMR
spectra are not given, as the integration of peaks corresponding to each hydrogen signal
belonging to the product of interest often produced fractional values, even when
normalizing integrals for sample peaks.
Samples were usually prepared from 10 to 20 mg of purified product reconstituted
in approximately 1 mL of CDCl3. Product purity was corroborated by TLC, and the exact
reason for the fractional integrals was difficult to pinpoint, but qualitatively, the spectra
confirm the identity of each substance analyzed.
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Figure 30. 1H-NMR of glycerol explaining the complex splitting observed over the
region from ~3.3 to 4.5 ppm. (Image retrieved from: https://chemistry.stackexchange.com
/questions/97786/h-nmr-equivalent-protons-and-coupling-of-glycerol)
Esterification of G-1,3-DS with Arachidonic
Acid to Form 2-AG-DS
Esterification of G-1,3-DS (the origin of which was from DHA-DS), with
arachidonic acid was achieved with thionyl chloride, selected primarily for the ease of
purification from by-products, SO2 and HCl, and amenability with the protecting group.
Figure 31 gives the 1H-NMR for 0.2 mL of a 1 mg/mL solution of arachidonic acid in
ethanol taken in approximately 1 mL of CDCl3. The signals for ethanol are readily
discernible in the spectrum, theirs being the most intense. The strong triplet at 1.2 ppm
corresponds to signals from the methyl group of ethanol, the quartet at 3.6 ppm
corresponds to the methylene protons of ethanol, and the broad singlet at 3.7 ppm
corresponds to the hydroxyl proton of the alcohol group of ethanol. The remaining peaks
belong to arachidonic acid (excluding the chloroform signal at 7.3 ppm). Given that
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arachidonic acid is a twenty-carbon polyunsaturated fatty acid, it is not surprising to find
that the methyl and methylene regions of the spectrum are perfuse with signals from the
hydrocarbon tail. A diagnostic multiplet at 5.3 ppm is produced by the methine protons of
the four double bonds (R-CH2-CH=CH-CH2-R) at carbons 5, 6, 8, 9, 11, 12, 14, and 15
of arachidonic acid. The complex signal at 2.8 ppm belongs to the methylene protons
adjacent to the previously mentioned methine protons. A distinct quintet at 1.7 ppm
belongs to the terminal methylene of the fatty acid tail (R-CH2-CH3) and the triplet at 0.8
ppm belongs to the terminal methyl group of the tail. Finally, a triplet at 2.3 ppm
corresponds to the methylene protons adjacent to the alpha carbon (the CH2 immediately
adjacent to the carbonyl of arachidonic acid). Beyond this, peak assignment becomes
difficult and speculative; the remaining multiplets at 1.2 and 2.1 ppm coming from the
remaining methylene groups of the fatty acid tail.

Figure 31. 1H-NMR of arachidonic acid (1 mg/mL solution in ethanol) in CDCl3.
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Figure 32 gives the 1H-NMR spectrum for 2-AG-DS. Successful esterification
was validated by two methods in conjunction. First, qualitative TLC verified that the
product isolated from the 2-AG-DS esterification step was pure, and second, the signals
for G-1,3-DS (Figures 28 and 29) and the signals from arachidonic acid (Figure 31) are
both present, as should be the case. Outside of minor signal shifts, the overlay of the
spectra from G-1,3-DS and arachidonic acid (excluding solvent traces; DMF in Figures
28 and 29 and ethanol in Figure 31) would produce a spectrum similar to the one present
in Figure 32. The percent recovery of 2-AG-DS is given in Table 10. All the recoveries
were lower than desired, the highest being 59%. Losses most likely occurred during the
basic aqueous wash, which was intended to convert any free arachidonic acid to its ionic
form (the pKa of arachidonic acid is 4.752 from https://pubchem.ncbi.nlm.nih.gov/
compound/231) thereby increasing hydrophilicity and allowing it to be washed away
from the much less hydrophilic 2-AG-DS. It is likely that 2-AG-DS was more water
soluble than thought, which is surprising given the structure of the protecting groups. The
lower temperature at which the reaction was performed to prevent oxidation and
degradation of the fatty acid could also contribute to lack of complete conversion,
resulting in lower yield. The use of fatty acid chlorides in the preparation of glycerides is
a well-established methodology (Bauer, 1946) and improvement in yield should be
possible.

67

Figure 32. 1H-NMR spectrum of 2-AG-DS in CDCl3.

Table 10
Percent Recovery of 2-AG-DS
Percent Yield
53.7%
59.1%
45.8%
Average
53 ± 7%

Deprotection Analysis Complications
The final step in the synthesis of 2-AG involved the cleavage of the t-BDPSi ether
protecting groups. As stated previously (see Table 5 in Chapter III), the first three
deprotection methods were not analyzed with HPLC but were purified and analyzed by
1

H-NMR. Figure 33 shows the 1H-NMR spectrum from method A, Figure 34 shows the

1

H-NMR spectrum from method B, and Figure 35 shows the 1H-NMR spectrum from

method C. Each 1H-NMR spectrum was consistent with 2-AG-DS, indicating that the
first three methods employed for deprotection were not successful at 0 °C after 8 hr.
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Minor differences do exist among the spectra, and are most likely attributable to the
presence of impurities (more visible with the signal amplification necessary to resolve all
peaks) owing to variances in purification and differences in the degree and accuracy of
instrument shimming (explaining why some signals appear more diffuse than others).

Figure 33. 1H-NMR of product in CDCl3 isolated from deprotection method A.

Figure 34. 1H-NMR of product in CDCl3 isolated from deprotection method B.
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Figure 35. 1H-NMR of product in CDCl3 isolated from deprotection method C.

This prompted interest in using HPLC to assess reaction progress, to allow a view
across time, and to aid in assessing overall deprotection success independent of having to
isolate the product. Since detecting free 2-AG is not practical with UV-Vis, the HPLC
method adapted from Rouzer et al. (2002) was intended to monitor reaction progress by
measuring the appearance of the primary by-product of deprotection, t-BDPSiF (Figure
23), which will absorb at 274 nm. Method D (Table 5) was a repeat of method C, using a
greater total molar concentration of acetic acid. Han and Razdan (1999) reported success
using this method, which prompted the second attempt. Method E was borrowed from a
cleavage method by Nikolaou and Webber (1986) that used a high concentration of
hydrofluoric acid as a fluoride ion source. The conditions were of interest given the
previously reported success of the cleavage of t-BDPSi ethers with these conditions.
Unfortunately, there were significant issues with both the deprotection methods and the
HPLC methodology.

70
The key issue with the HPLC methodology can be seen in Figure 36, which
shows a chromatogram of the 50 mg/mL standard solution of t-BDPSiF. The preparation
of standards is given in Chapter III, but to give a brief generalized review, t-BDPSiF was
generated from t-BDPSiCl by incubating 109 mg with 2.5 molar equivalents of fluoride
ion (from TBAF) in THF which contained the anti-oxidant BHT. After quenching any
remaining fluoride ion with MgCl2 and filtering the precipitate (MgF2), standard solutions
were diluted from this 109 mg/mL stock and were chromatographed via HPLC in 20 µL
aliquots. Each of the chromatograms had a similar qualitative appearance as the one in
Figure 36, containing multiple signal peaks when only one was anticipated. At the time, it
was presumed that the peak corresponding to t-BDPSiF would be apparent when peak
areas were matched to sample concentrations; that a linear relationship would reveal the
correct peak. This was an erroneous assumption, however, as several peaks produce a
linear relationship when graphed versus the concentration of the t-BDPSiF standards.
Some of the compounds contributing to the extraneous peaks are tetra-n-butyl ammonium
cation (TBA+) and BHT, both of which absorb at 274 nm and would have a linear
relationship when their peak areas were plotted against t-BDPSiF standard concentrations
because they were diluted by the same factor. Acetic acid also weakly absorbs at 274 nm,
and oxidized products of BHT could potentially be contributing signals as well.
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Figure 36. HPLC chromatogram of 20 µL of 50 mg/mL t-BDPSiF. There are five
distinctive peaks occurring at: 1.9 min, 5.0 min, 7.6 min, 8.9 min, and 10.1 min.

Sample aliquots taken from methods D and E analyzed by the same HPLC
method also contained unknown peaks. Figure 37 shows the HPLC chromatogram of a
sample aliquot from method E after 24 hr. The peak profile of the chromatogram aligns
with the peak profile of the t-BDPSiF standard chromatogram from 0 to 10 min, which is
confirmation that there is at least t-BDPSiF present in the sample; meaning deprotection
had occurred. However, without a concrete way of assessing which peak belonged to tBDPSiF, drawing conclusions from the data set is very difficult.
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Figure 37. Chromatogram of 24 hr aliquot from Method E. The sample was diluted 100fold prior to analysis (retention times for a sample calculation using this chromatogram
are inset in the upper right corner)

Another series of standards was planned in an attempt to resolve these peak
identity issues, but several new challenges came along with further analysis. The goal
was to obtain clean standards of TBAF, THF, t-BDPSiCl, and t-BDPSiF so that tBDPSiF elution time could be pinpointed by process of elimination and then correlated
back to the chromatograms from method D and E, abrogating the necessity of running
further deprotection trials. A stock solution of 103.7 mg/mL t-BDPSiF was prepared
again as before, by incubating 103.7 mg t-BDPSiCl with 250 mg of TBAF for 24 hours.
The only variation was the use of approximately 1.0 g of SiO2 granules instead of MgCl2
to scavenge excess fluoride ion from solution prior to sample analysis.
Instrument availability, and consideration for other work being performed at the
time, required a change in the column used for the new trials, which was potentially a
complicating factor. A reverse phase C18 Phenomenex column (4.6 mm x 150 mm; silica
particle size 2.5-2.8 μm) was used instead of the Phenomenex Luna Omega Polar C18
column previously used. It was hoped that the columns would not be so disparate in
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resolution that the results would be unrelatable to the earlier samples. The following
figures are from the same HPLC methodology using the reverse phase C18 Phenomenex
column. Figure 38 displays a chromatogram of 20 µL of THF (containing BHT), Figure
39 displays a chromatogram of 20 µL of a 10 mg/mL solution of TBAF in THF, Figure
40 displays a chromatogram of 20 µL of pure t-BDPSiCl and Figure 41 displays the
chromatogram for 20 µL of the stock solution of t-BDPSiF (concentration = 103.7
mg/mL). Unfortunately, as before, each standard contained multiple peaks making peak
assignment problematic. For instance, in Figure 39 (TBAF in THF) there are a host of
overlapping peaks from approximately 1.0 to 3.0 min. These peaks were determined to be
contaminates adhering to the column. Flushing with mobile phase at 1.5 mL/min for
several hours did not help to alleviate this issue. Knowing the origin of these peaks
(contaminates from previous analyses) allows them to be dismissed as candidates for
TBAF, but there are several peaks outside of the 1.0 to 3.0 min range that need to be
identified, specifically at 4.253 min, 4.981 min, 8.994 min, and a peak at approximately
11 min.

Figure 38. HPLC chromatogram of 20 μL of THF containing BHT.
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Figure 39. HPLC chromatogram of 20 µL of approximately 10 mg/mL TBAF solution in
THF.

Figure 40. HPLC chromatogram of 20 μL of t-BDPSiCl.
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Figure 41. HPLC chromatogram of 20 µL of 103.7 mg/mL t-BDPSiF in THF.

Analysis of the standards to identity which of the peaks was t-BDPSiF was
attempted, but it was still difficult to make this determination. For example, the standards
prepared in THF concomitantly contained BHT, at a concentration between 0.025 to
0.04% (m/v), which includes the chromatograms in Figures 38, 39, and 41. It should have
been possible to use the chromatogram of THF (Figure 38) to pinpoint the elution time of
BHT, which then might have helped to identify TBA+ in the chromatogram of TBAF
(Figure 39), which would then allow both of those peaks to be eliminated from t-BDPSiF
(Figure 41) giving the elution time for t-BDPSiF. This was not the case, however, as the
peak profile of the chromatogram for THF contained unique peaks apart from the
chromatograms of TBAF and t-BDPSiF (at 5.586 min), an unexpected result that
confounded proper identification more than bringing clarity. Trying to work with the
chromatograms to make other peak assignments was not possible either. In short, running
further qualitative standards did not help in peak assignment.
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Discussion of High Performance Liquid
Chromatography Data
Although there were difficulties and ambiguities present in the HPLC data, there
is still clearly the presence of t-BDPSiF in the sample aliquots from method E (see
Figures 36 and 37) as established previously. Without a definitive peak assignment,
assessing percent total deprotection of 2-AG-DS is impossible, but it is still possible to
assess potential extent of deprotection by looking at each peak that might be t-BDPSiF
and analyzing accordingly. This allows an establishment of a minimum/maximum for
deprotection that occurred.
Figure 36 gives the chromatogram from the 50 mg/mL t-BDPSiF. There are five
peaks of interest within this chromatogram, occurring at 1.9 min, 5.0 min, 7.6 min, 8.9
min, and 10.1 min. Standard curves of the peak area vs concentration at each retention
times were generated from the HLPC data from the standards (100 µg/mL, 1 mg/mL, 10
mg/mL, 50 mg/mL, and 109 mg/mL). In sequence of increasing elution time, these
graphs are given in Figures 42, 43, 44, 45, and 46. In each case, save for the standard
curve for the peak at 1.9 min, the 109 mg/mL standard was discarded as an outlier,
improving overall linearity for each graph. As can be seen in Figure 42, there is no linear
relationship for the graph generated from the data set at 1.9 min, which is why this data
set was disregarded for further analysis. Looking at Figures 43, 44, 45, and 46, there are
clear linear trends of varying precision, as measured by the linear correlation coefficients
(R2) provided for each under the trendline equations.
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Figure 42. Standard curve for t-BDPSiF using 1.9 min peak
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Figure 43. Standard curve for t-BDPSiF using 5.0 min peak
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Figure 44. Standard curve for t-BDPSiF using 7.6 min peak
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Figure 45. Standard curve for t-BDPSiF using 8.9 min peak
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Figure 46. Standard curve for t-BDPSiF using 10.1 min peak

To gauge potential deprotection, each of these standard curves were analyzed with
the concomitant data from the chromatograms from deprotection methods D and E.
Table 11 gives the results of this analysis. Referring to Figure 36, the chromatogram for
the 50 mg/mL t-BDPSiF standard, the insert for the 10.1 min peak area is given in the
upper right corner of the chromatogram. This chromatogram was generated from the
24 hr aliquot from deprotection method E and was diluted 100-fold prior to analysis. A
sample calculation for the generation of the values in Table 11 is given below for
reference.
Sample calculation for percent deprotection from Method E
0.257 g 2-AG-DS into 5.140 mL = 50 mg/mL
50 mg/mL x .02 mL ÷ 855.1 g/mol = 1.17 x 10-3 mol
[(20784 x 100) – 1 x 106]/243604 = 4.43 mg/mL
4.43 mg/mL x .02 mL ÷ 258.41 g/mol ÷ 2 = 1.72 x 10-4 mol
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Percent deprotection = (1.72 x 10-4 mol ÷ 1.17 x 10-3 mol) x 100% = 14.6%
Table 11
Potential Percent Deprotection for Methods D and E
Peak elution
5.0 min
7.6 min
8.9 min
Method D (24 hr)
< 0.3%
< 0.3%
N/A
Method E (3 hr)
< 0.3%
< 0.3%
< 0.3%
Method E (24 hr)
15.2%
< 0.3%
N/A

10.1 min
< 0.3%
< 0.3%
14.6%

To explain the data in Table 11, there were three general outcomes from analysis.
The first would be a negative result, which was interpreted as deprotection that fell below
the lower limits of detection, which would mean deprotection less than 0.3%. The lowest
t-BDPSiF standard analyzed was 100 µg/mL. Thus:
0.1 mg/mL x 0.02 mL ÷ 258.41 g/mol ÷ 2 = 3.87 x 10-6 mol
3.87 x 10-6 mol ÷ 1.17 x 10-3 mol = .003 = 0.3%
The second was a result in excess of 100%, which is obviously not physically possible,
and could indicate one of two errors. Either the peak being analyzed was simply not
t-BDPSiF or the peak was a combination of compounds that absorb at 274 nm eluting
together. These results were denoted with N/A. Finally, some results were considered
valid, and are reported in the table accordingly. From this data set, it is possible to at least
comment on the potential efficacy of each deprotection method. It seems that method D
(6 mol equivalents of TBAF with 6 mol equivalent of acetic acid) is essentially noneffective, while method E (10 mol equivalents of HF with 1 mol equivalent of pyridine)
is sparingly effective, with a potential maximal deprotection of approximately 15% after
24 hr.
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2-Arachidonoyl Glycerol
Recovery Outcomes
As mentioned previously in Chapter III, fractions were collected from the HPLC
as they eluted at time points that corresponded to elution of 2-AG in the Rouzer et al.
(2002) HPLC methodology (the basis for the method used). The goal was to determine
where 2-AG was eluting in the hope that purification of 2-AG could be accomplished via
HPLC by scaling up to a preparative column. Unfortunately, none of the fractions
collected and screened via 1H-NMR showed any sign of 2-AG. Given the results in Table
11, a simple explanation of this outcome might be that there was no 2-AG to collect, but
some of the fractions collected did contain compounds that might have been a fatty acid
by-product of the breakdown of 2-AG, indicating that the fluoride ion concentration
might have been too strong.
Figure 47 shows an 1H-NMR from a fraction collected at 15.88 min from
deprotection Method D. The HPLC method adapted for screening deprotection methods
originally reported elution of 2-AG at 15 min and 1(3)-AG at 15.5 min (Rouzer et al.,
2002). Carbonyls will absorb in the UV-Vis spectrum with a maximum at 275 nm
(Bayliss & McRae, 1954), so the presence of a peak here might have been indicative of
either 2-AG or its isomer(s). The NMR signals had to be amplified considerably to be
detected and fell exclusively between 0.0 to 3.2 ppm (save for the broad singlet at 4.7
ppm from HOD, the deuterated solvent used for this 1H-NMR). Parts of the sample
profile appear to match the fatty acid tail of 2-AG, with multiplets at 3.05 ppm and 1.55
ppm, a triplet at 0.8 ppm, and a sextet at 1.25 ppm. However, the signature methine
multiplet at 5.5 ppm is entirely absent, as well as many other characteristic signals for 2AG, which is suggestive that the sample is some by-product from the breakdown of 2-AG
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or 2-AG-DS, although it could potentially be some entirely unrelated substance eluting
from the column. With the limited data available, it is difficult to make definitive
statements as to the identity of this compound, but the time at which it elutes and the 1HNMR profile suggests that it is some kind of hydrocarbon, but it is neither 2-AG-DS nor
2-AG. Most fractions screened via 1H-NMR did not contain any detectable compounds,
and the collection of analyzable material from each 20 µL fraction was so scant that
analysis beyond NMR was not feasible.

Figure 47. 1H-NMR of 15.88 min fraction from HPLC collected at 20 hours total run time
from deprotection Method D.

Single Flask Synthesis of 2-PG-DS
in Dimethylformamide Using
Thionyl Chloride
Running deprotection methods A through E exhausted all remaining available 2AG-DS. In the course of preparing new standards to resolve peak identity in the HPLC
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chromatograms, the synthetic method for the preparation of 2-AG-DS was concomitantly
reviewed. Up to this point, each intermediate from each synthetic step was isolated,
purified, and characterized. This inevitably resulted in some minimal loss of product and
time, as certain synthetic intermediates were more amenable to isolation and purification
than others. Consequently, palmitic acid, a 16-carbon saturated fatty acid, was utilized in
place of arachidonic acid during synthetic methodology development due to its cheaper
price and suitability as a fatty acid substitute for arachidonic acid. The results from the
deprotection methods screened up to this point demonstrated that amending previous
methods that proved successful with deprotection of t-BDPSi ethers were seemingly not
as successful as they were expected to be, and so returning to palmitic acid for the
purposes of blanket screening more deprotection methods was immediately appealing.
It was established previously that DMF is the superior solvent for the formation of
silyl ethers using the Corey methodology (Patschinski et al., 2014) at least in terms of
reaction kinetics. Screening deprotection methods with a doubly silylated 2-palmitoyl
glycerol compound would allow basic vetting of deprotection conditions that might be
suitable for 2-AG-DS, but ultimately, given the unique stability constraints in using
arachidonic acid, 2-AG-DS must still be screened separately in any conditions
demonstrating successful deprotection (greater than 80% yield would be the goal). If
there were a way to produce 2-AG-DS or the palmitic acid derivative (2-PG-DS) in a
single reaction flask without the need for purification and transfer to a new reaction
solvent in-between steps, it would be incredibly helpful for the purposes of screening and
to ameliorate the need to isolate each intermediate and so lose potential product.
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By using DMF as a solvent, however, there is a potential issue with the synthetic
methodology. DMF itself contains a carbonyl, which should be reactive with thionyl
chloride, potentially causing a cross reaction with the solvent, rendering this reagent and
reaction pathway ineffective. However, this is not in fact the case, as the reaction of
thionyl chloride with DMF generates a reactive chloroimium ion that then proceeds to
react with free palmitic acid (or G-1,3-DS) to produce the fatty acid chloride that then
proceeds to generate the ester. Figure 48 details this mechanism (Arrieta, Aizpurua, &
Palomo, 1984).

Figure 48. Mechanism for the generation of palmitoyl chloride with thionyl chloride.
Note that the chloroinium ion generated may react with either palmitic acid or G-1,3-DS;
whichever nucleophile it encounters first.

A reaction was set up to test the outcome for the synthesis of 2-PG-DS using
glycerol as a starting material with the synthetic methodology described in Chapter III
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but without isolating or purifying products in each step. The only alteration to the
methodology in Chapter III was the performance of the esterification step at ambient
temperature (21-23 °C) to hopefully improve yield. Figure 49 shows the 1H-NMR of the
product isolated by liquid-liquid phase extraction of the DMF reaction mixture with 5 mL
aliquots of hexane three times. The product matches the expected 1H-NMR profile of 2PG-DS. Signals in the 0 to 3 ppm range characteristic of the fatty acid tail are present,
namely a 0.8 ppm triplet corresponding to the terminal methyl, a sextet at 1.6 ppm
corresponding the adjacent methylene of this terminal methyl, and a triplet at 2.35 ppm
corresponding to the methylene adjacent to the carbonyl. Further signals from the fatty
acid tail methylenes exist as diffuse and overlapping multiplets between 1 and 2 ppm.
The aromatic signals from the protecting group are clearly present in the corresponding
region between 7 to 8 ppm. Finally, the telltale signals for glycerol occur in the region
between 3.5 to 4.4 ppm and is shown on a zoomed in scale in the inset in Figure 49. This
1

H-NMR spectrum produced the sharpest and clearest signals of the splitting of the

methine and methylene hydrogens from glycerol (Figure 30) to this point, demonstrating
clearly that the generation of doubly silylated monoglycerols is achievable using DMF
and thionyl chloride in tandem. The most welcome feature of the 1H-NMR is the fact that
it is free of signals belonging to DMF, showing that purification, from the reaction
solvent was complete. Table 12 gives the percent recovery for 2-PG-DS, showing a
marginal improvement from before.
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Figure 49. 1H-NMR of 2-PG-DS

Table 12
Percent Recovery of 2-PG-DS.
Trial
1
2
Average

Percent Recovery
60.7%
77.1%
69 ± 12%

Deprotection of 2-PG-DS
Three different trials were conducted to screen new deprotection conditions using
the newly synthesized 2-PG-DS. The trials were modifications of the original Corey
deprotection method (Corey & Veknateswarlu, 1972) utilizing TBAF in THF at higher
concentrations than utilized previously. Concentrations of TBAF employed were 0.5, 1.0,
and 2.0 M. Deprotection was carried out for 24 hr at 0 °C under inert conditions and
sample aliquots were taken and analyzed using the same HPLC method and the C18
Phenomenex column. Unfortunately, as before, deprotection results were difficult to
interpret given the presence of multiple, unidentifiable peaks in the HPLC
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chromatograms. The maximum amount of t-BDPSiF detected in-situ from HPLC analysis
would place deprotection at 75.9%, but the chromatograms had ambiguities as before,
and it is dubious whether that result is accurate. Figure 50 shows a graph of the peak area
vs time for aliquots taken from the 1.0 M TBAF deprotection trial. The initial two data
points on the graph seem to show a linear trend, a good sign that this might have been
t-BDPSiF, however, the next two aliquots returned less total area, corresponding to less
concentration, than the preceding reading. This was an unexpected result, but if accurate,
it might imply that with increasing time t-BDPSiF was degrading. The final reading
showed an increase in area once again, however, debunking that idea entirely and
suggesting that either the standards were inaccurate or there were issues with the HPLC
column or detector.
The presence of such trends in the data set generated from these deprotection
trials is why they are excluded from this paper. As was stated previously, the difficulties
that materialized in analyzing the deprotection methods via HPLC indicate that further
work needs to be done to resolve these issues if HPLC is to be used further.
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Figure 50. Peak area vs time for 2-PG-DS deprotection utilizing 1.0 M TBAF in THF.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide
Assay Results from CRL 1682 Cells Treated
with Phytocannabinoid Extracts
Without the recovery of 2-AG, it was obviously not possible to screen cancer
lines using the MTT assay with that compound; however, proof of the usefulness of this
assay as a tool for measuring cancer cell culture response to cannabinoids can be seen in
the following assays conducted using extracts from samples of marijuana containing the
phytocannabinoids THC and CBD.
Figure 51 gives the MTT cell proliferation assay results for increasingly dilute
treatments prepared from extracts from a marijuana sample with high THC content. The
solutions were diluted an order of magnitude between each treatment well series. The
cancer line being treated was a pancreatic cancer cell line, CRL 1682. The assay results
show a proliferation pattern that is not uncommon for cannabinoids, where certain
concentrations can enhance growth (as in the first two treatment concentrations) but then
a concentration range, typically in the µM range, is reached where growth is completely
abrogated (the next two treatment concentrations). Eventually, with continuing dilution, a
growth enhancing effect returns (the final two treatment concentrations). Figure 52 shows
an MTT cell proliferation assay of another extract of marijuana, a sample containing high
amounts of THC and CBD. The results from this assay show a consistent antiproliferative effect for each increasingly dilute treatment (save for the undiluted extract),
showcasing how combinatorial treatments utilizing multiple different cannabinoids with
different affinities for the CB receptors can achieve treatment outcomes that are more
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universally positive, and therefore, desirable. Results such as these clearly demonstrate
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why cannabinoids warrant investigation as anti-cancer agents.
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Figure 51. MTT cell proliferation assay of pancreatic cancer cells (CRL 1682) treated
with high THC extract solutions. Extracts are ten-fold dilutions of a plant sample extract.
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Figure 52. MTT cell proliferation assay of pancreatic cancer cells (CRL 1682) treated
with THC/CBD extract solutions

CHAPTER V
CONCLUSIONS
Current Status
The results of this research demonstrated that tert-butyldiphenylsilyl chloride is
an appealing protecting group to generate protected 2-monoglycerols (in this case 2-AGDS or 2-PG-DS) from both DHA and glycerol, although not without draw backs. The
discovery that the synthetic methodology could be carried out in a single reaction flask
using the kinetically favored solvent, DMF, while still producing a good yield with
SOCl2 is an appealing quality of this protecting group. Unfortunately, conditions
employed to remove the protecting group seemed to be ineffective; however, given issues
that were encountered with the methods employed to assess deprotection, this was not
definitively established and bears further investigation.
The primary issue in assessing deprotection was acquiring pure standards to
confirm peak identity of compounds absorbing at the wavelength of interest (274 nm).
Without a way to pinpoint which peak belonged to which compound, interpreting the
deprotection method effectiveness by HPLC becomes extremely difficult; which is why
deprotection was given as a potential value. The additional confounding peaks in the
standards have several potential origins. First, the HPLC columns used in screening
standards and samples were additionally used for the analysis of other cannabinoid
extracts and other laboratory samples. The removal agent employed in all deprotection
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methods, fluoride ion, forms strong single bonds with Si, the Si-F bond dissociation
energy being 540 kJ/mol compared to the bond dissociation energy of Si-C of 435 kJ/mol
(https://labs.chem. ucsb.edu /zakarian/armen/11---bonddissociation energy.pdf), which is
why it is widely employed to remove silyl ether protecting groups. This is also why the
scavenging of free fluoride ion from sample aliquots with Mg2+ or silicon dioxide was
vital before loading onto the column, as silica is the linker for the 18-carbon alkyl chain
that constitutes the stationary phase for the reverse phase columns used in screening
samples. It is possible that the sample depicted in Figure 48 (Chapter IV, page 82) that
appeared to be a component of the fatty acid tail of 2-AG was in fact part of the C-18
stationary phase that was liberated if fluoride ion attacked the silica column packing.
Passage of injected samples through the column could also have liberated components
adherent to the C-18 stationary phase through Van der Waals interactions, causing elution
at sporadic times, which might explain the unexpected peak at 5.586 min in Figure 38.
Although each sample was treated to ensure no free fluoride ion was allowed onto the
column, it is unclear how even minute amounts introduced would impact column
integrity and use, and this consideration was one reason further HPLC analysis was not
pursued past the second series of standards.
It is my contention that deprotection was probably not as scant as what was
detected. From the data for the deprotection trials conducted with 2-PG-DS, the
maximum calculated deprotection was 75.9% (determined by blanket screening all
pertinent peaks returned from aliquot analysis and treating as t-BDPSiF in an identical
process detailed in Discussion of HPLC data on page 76), which is closer to the extent of
deprotection reported previously (Nicolaou & Webber, 1986), but as discussed, given the
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discrepancies in the data as a whole, it would be inappropriate to present this as a
conclusion. The conditions used should have been more effective than detected. The
removal conditions need to be able to be accurately assessed before attempting to screen
further.
Return on yield prior to esterification was excellent. The esterification with
thionyl chloride was less effective, showing improvement when conducted at ambient
temperature. Increasing reaction temperature and adjusting reaction time could improve
yield, while still avoiding unwanted side reactions, especially if carried out under inert
conditions, as the oxidation of 2-AG and 2-AG-DS would be the greatest contributor to
by-product generation and product loss at this stage. With these adjustments, the
methodology could outperform other currently published procedures, and based upon the
data obtained thus far, these adjustments should be readily implementable.
Based upon retrospective evaluation of the analytical methods and techniques
employed for this research, there are several modifications that would potentially be
fruitful. The first and most obvious, if the deprotection issues are in fact a reality, would
be utilizing a different silyl ether protecting group for protecting DHA or glycerol.
TMSCl (trimethyl silyl chloride) would be an interesting protecting group to evaluate,
given its ease of removal in comparison to t-BDPSiCl (Greene & Wuts, 1999). It might
be the case that TMSCl would not be amenable to use with SOCl2, but it is the most
labile of the silyl ethers and its substitution would be a sensible next step in evaluation of
these protecting groups with this methodology.
Furthermore, qualitative TLC was consistently used as a tool to evaluate reaction
completion and product purity, but in each case, a polar stationary phase was used. The
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results of the HPLC analysis and 1H-NMR spectra indicate that products isolated might
not have been pure. For instance, in Figures 28 and 29, the methyl and aromatic regions
of these spectra contain additional unexpected peaks. The presence of these peaks
indicates that there is likely a by-product from a previous step, namely the hydrated form
of the protecting group, t-BDPSiOH, which is contributing the extraneous signals in those
regions. Analysis of products isolated from intermediate synthetic steps via HPLC would
be a more accurate, although time consuming, way of establishing product purity prior to
1

H-NMR analysis.
Finally, qualitative TLC was frequently used to gauge reaction completion and

product purity, but as established, the presence of extraneous peaks in 1H-NMR spectra
indicate that the resolution was not sufficient to properly assess either. One improvement
that could be made in this regard would be employing C-18 stationary phase for TLC and
any column chromatography used to attempt to purify product. Given that HPLC analysis
revealed the presence of multiple peaks in sample aliquots, it is possible that by-products
carried from earlier reactions were contributing these additional signals, and since reverse
phase HPLC columns were used, it is highly likely that the use of reverse phase in other
analytical techniques employed would be helpful in resolving by-products or in the
purification of product in intermediary steps.
Future Work
A treatment modality that cannabinoids could be incorporated into with great
therapeutic effect would be chemotherapy. Chemotherapeutic agents are typically known
for their unwanted toxicological side effects (Cella & Cherin, 1988), but other practical
difficulties involved with their use range from poor bioavailability, the development of
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multiple drug resistances to these compounds, complications arising from lack of
specificity for cancer targets, and simply poor therapeutic indices; many of these issues
being directly conflated with the larger doses intended to increase efficacy against their
target (Senapati, Mahanta, Kumar, & Maiti, 2018). One route being investigated to
address these issues is the use of vehicles, such as lipid-based niosome (non-ionic
surfactant-based vesicle) nano-carriers to facilitate the carry and delivery of hydrophilic
drugs to tumor sites for targeted therapy (Naderinezhad, Amoabediny, & Haghiralsadat,
2017). The association or sequestration of drugs with poor bioavailability with(in) lipidbased carriers served as inspiration for a possible use of 2-AG as a hydrolyzable drug
"sheath." The goal of this combination would be to improve the overall bioavailability of
both compounds by chemically bonding them; eliminating hydrogen bond donors in 2AG, and adding more lipophilic character to small, poorly water-soluble
chemotherapeutic agents. Figure 53 shows a model of this concept with
aminoglutethimide (bracketed).
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Figure 53. Aminoglutethimide drug "sheath" concept
Aminoglutethimide is an aromatase inhibitor used to treat hormone-dependent
breast cancer after first line treatments, such as tamoxifen, have proven ineffective
(Patrick, 2013). The log P (where P is the partition coefficient; the ratio of the
concentration of a substance across two immiscible solvents, in this case, concentration in
1-octanol over concentration in water) of aminoglutethimide is 1.2 (https://pubchem
.ncbi.nlm.nih.gov/compound/ aminoglutethimide), whereas the log P for 2-AG is 5.3
(https://pubchem.ncbi.nlm. nih.gov/compound/2-arachidonoylglycerol), placing 2-AG in
excess of Lipinski's recommended log P ≤ 5 (Patrick, 2013). However, bound together as
in Figure 53, a hydrogen bond donor is eliminated, and the amalgamation will probably
have a log P in between the two values of 1.2 and 5.3, making it closer to Lipinski’s
recommendation.
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This example is not perfect, as the combined molecular mass is in excess of the
recommended 500 Da (combined MW = 620.79 g/mol) and aminoglutethimide is a
perfectly serviceable drug on its own, and it is not clear that using it in this treatment
method would be beneficial or even warranted. As a demonstration of a concept though,
it is a good example to highlight a potential useful application of 2-AG. Such unions
could boost overall efficacy through an entourage effect, once the molecule is hydrolyzed
into its constituents. This could potentially give a more positive treatment outcome
compared to the presentation of the drugs in isolation or even in synchrony. This is
essentially identical to combinatorial therapy, but the kinetics of hydrolysis/dissociation
might afford a different reactivity profile that would be worthwhile screening against cell
culture. So long as the molecular weight of the compound being "sheathed" can be
maintained in the neighborhood of 200 Da, and that the functional attachment to 2-AG
does not require modifying either compound to the point of inactivity or toxicity, then
there is no theoretical limit to what could be placed within the monoglyceride.
Specificity for the desired target (the cancerous cells) is still an issue that is not
resolved with this idea. However, given the data supporting the relatively non-toxic
nature of cannabinoids to non-cancerous cells and their use as anti-emetic and painrelieving agents (Velasco et al., 2012), it might be the case that this treatment method
would be more suited to use in conjunction with non-specific, anti-proliferative
chemotherapy treatments. Utilized in this manner, the hydrolysis back into the
constituents would theoretically produce effects that are more anti-proliferative while
concomitantly counteracting at least the sensation of the unwanted physiological side
effects (pain and nausea).
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There are obvious difficulties with this technique, however. The first would be
obtaining a ready source of 2-AG that is activated at the terminal carbon of the fatty acid
tail, such as 20-hydroxy-arachidonic acid, which to my knowledge represents a major
hurdle already, this compound costing hundreds of dollars for microgram quantities
(https://www.sigmaaldrich.com/catalog/product/sigma/h3023?lang=en&region=US).
Furthermore, SAR studies to date have revealed the necessity for 3-4 double bonds in the
fatty acid tail for proper activity at the CB receptors; fewer than that leads to inactivity
(Mechoulam and Ben-Shabat,1999). Preliminary SAR studies looking at fatty acid chain
substitutions, either of arachidonic acid, or complete substitution with a leukotriene or
prostaglandin derivative, have shown lack of activity, save for one exception, 12(S)hydroxy-arachidonoyl ethanolamide, which will bind to CB1 (Mechoulam et al., 1998).
These data reveal that finding a suitable cost-effective substitute might be challenging.
Another route to increase 2-AG efficacy and potency would simply be
modification of the compound itself, which was of primary interest and one of the major
reasons direct synthesis was chosen. By examining published SAR data for model
compounds, crystallography data for CB1, and giving priority to emerging drug design
needs when making structural decisions, several interesting routes for modifying 2-AG
exist that are worth exploring. As mentioned previously, SAR studies for 2-AG are not
well published, but Mechoulam's group has purportedly forthcoming results indicating
that 2-AG rudimentarily mirrors anandamide regarding SAR (Mechoulam et al., 1998).
The 1(3) isomer of 2-AG was reported as binding to both CB receptors with similar
potency as 2-AG, and the fatty acid derivatives 2-palmityoyl glycerol and 2-linoleoyl
(18:29,12) glycerol showed no activity at either CB1 or CB2. This is in keeping with the
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previous SAR findings where three to four double bonds were necessary for proper
binding. Figure 54 gives the structure of anandamide and SAR information for this
compound.
The SAR information for anandamide can be used to help inform 2-AG
modification, but beyond that, an interesting piece of information concerning the
conformation that 2-AG assumes when binding to CB1 was given by Hua et al. (2016) in
their crystallography study of the CB1 receptor, namely that 2-AG takes a "C-shaped"
conformation (see Figure 5) in the pocket of CB1 and is predicted to bind similarly to that
of THC. If the binding mode is similar to THC, it might also be possible to utilize SAR
for THC to look for structural modifications for 2-AG to improve its efficacy. Prior to
examining the SAR for THC, an attempt at demonstrating the overlay of these two
compounds is presented in Figure 55. This figure does not necessarily reflect the actual
conformation of 2-AG within the binding pocket, but simply gives a baseline upon which
to form the following discussion. Without a rudimentary comparison, any SAR
information concerning THC would be difficult to translate to 2-AG.
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Figure 54. Anandamide SAR information. (Adapted from Mechoulam et al., 1998.) Each
numbered SAR element (below) that corresponds to a specific part of the structure is
numbered in the figure to facilitate discussion. 1) Double bonds must be ≥ 3-4 or activity
is abrogated. 2) The unsubstituted amide is inactive. Mono-alkylation (substitution of the
N-ethanolamide) up to a branched pentyl group exhibits significant activity, following the
trend: C5H11 < CHMeCH2Me < n-C4H9 < t-C4H9 < CH3 < C2H5 < C(CH3)2, < n-C3H7. 3)
N,N-dialkylation leads to loss of activity. 4) Hydroxylation preserves activity, but is
lowered. 5) The methyl ether and phosphate are less active than the parent alcohol.
Carbonyl derivatives are inactive. 6) In the n-3 series (in Mechoulam’s figure, n-x is the
designation used to signal where the double bond series begins, so n-3 would be the third
carbon starting from the terminal carbon of the fatty acid tail, similar to the Ω numbering
system for fatty acids; 3-4 double bonds are necessary for activity but their sequence is
flexible), derivatized ethanolamides are either inactive or less active than related
compounds in the n-6 series. 7) Alkylation or di-alkylation of the α-carbon preserves
binding; methylation or di-methylation potentiaties and increases activity. 8) Chiral
centers on N-alkyl substituents lead to radically altered Ki. 9) Replacing the -OH with -F
leads to a 10 fold increase in binding to CB1. 10) Conjugation of the double bonds leads
to reduced activity. 11) Branching of the fatty acid tail enhances binding.
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Figure 55. Overlay of 2-AG (red) with THC (black), attempting to show potential
similarity in binding

Figure 56 is a diagram of THC outlined for discussion of SAR elements for this
compound. Although numerous major pharmacophores are present within THC, one of
the main moieties responsible for variation in receptor binding parameters is the C3 side
chain. The chain has a minimum length requirement of three carbons and was
characterized as being ideal at 5-8 carbons (Bow and Rimoldi, 2016).
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Figure 56. Diagram of THC outlining pertinent pharmacophore moieties
Table 13 gives the relationship between chain length and respective Ki for THC
modified at C3 for CB1. This relationship coincides nicely with the overlay presented in
Figure 56, in the sense that it is easy to mentally add additional carbons at C3 for THC
and see how they could conform to the backbone of the fatty acid tail of 2-AG.
Furthermore, SAR studies examining modifications of the chain at C3 show that
dimethylation of C'1 (the first carbon of the chain) and a total of eight carbons in the
chain length (1,1-dimethyloctane) gives a Ki of 0.9 nM, a full order of magnitude below
that of the ideal chain length in Table 13. Further SAR on C3 showed that the
introduction of alkyne functional groups (rigidity) have varying degrees of effects on Ki
constants for THC, usually being positive in nature. These data are indicative of the
necessity of rigidity within the fatty acid linked to glycerol for appropriate binding.
Studies looking at restriction of the orientation of the chain itself have shown that when
the chain is locked into a downward conformation (away from the bulk of the molecule,
specifically the C1 phenol), it is the more kinetically favored orientation (Bow and
Rimoldi, 2016).
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Table 13
Relationship Between C3 Chain Length of THC and CB1 Affinity as Measured through
Ki. (Adapted from Bow and Rimoldi, 2016).
Chain Length
Ki (nM)
1
n/a
2
n/a
3
75.4
4
65 ± 13
6
41 ± 3.8
7
22 ± 3.9
8
8.5 ± 1.4

Modification of the C1 phenol has the general effect of increasing CB2 specificity,
both with removal or methylation. Modification of the phenol beyond methylation tends
to abrogate activity at both receptors, showing the sensitivity of the receptor to this group.
Modification at the C9-C11 group does not confer variable selectivity but impacts
receptor affinity. Specifically, the replacement of C9-11 with a carbonyl confers an order
of magnitude increase in Ki for CB1 and CB2, and the THC derivative generated is
identical to Cesamet® (generic nabilone) which is a medication prescribed to attenuate
decreased appetite and the secondary wasting associated with chemotherapy (Bow and
Rimoldi, 2016).
Based upon the SAR for THC and the fact that substitution of the hydroxyl group
in anandamide increases CB1 affinity, the following permutations of 2-AG are anticipated
to be worth investigating for their increased affinity for CB1 (Figure 57). Increased
receptor affinity for a drug class is desirable if steady state concentrations are difficult to
reach a therapeutic concentration but is generally appealing for the ability to minimize
dosing requirements or if dose directly scales with therapeutic efficacy. It is appealing to
modify 2-AG in this way given its transient nature in physiological conditions; increased
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efficacy could potentially render a compound with physiologically beneficial effects
which is essentially benign when metabolized/hydrolyzed. Glycerol's ultimate
physiological fate is connected with benign intersections with carbohydrate/lipid
metabolism, and arachidonic acid has multiple biological fates, but most likely would be
sequestered into a biological membrane, outside of situations where it would be
incorporated into an alternative metabolic pathway (such as COX-1/2-mediated
prostaglandin synthesis).

Figure 57. Suggested modification of 2-AG. Three possible permutations are of interest,
with the distinction between the three being substitution at X, with the variable
substitutions being: 1) -H, 2) -OH, 3) -CH3.
The goal with the proposed modification to 2-AG is two-fold. First, from the SAR
discussed previously, there is the potential to increase CB1 affinity by expanding the
molecule into the shallow pocket filled by arm 3 of AM6538 described in Figure 9. This
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pocket is what N-alkyl extensions on anandamide occupy (Hua et al., 2016) and must be
host to a cationic amino acid residue at its basin, as evidenced by the order of magnitude
increase in CB1 affinity when substituting an electronegative fluorine or chlorine atom for
the -OH in anandamide. The second is to preserve the overall water solubility of 2-AG.
Figure 57 shows a series of proposed modifications to 2-AG, seeking to meet both these
goals. The addition of the substituted fluorobenzene at the 1 position of the glycerol is
meant to fill into arm 3, with the hope that the steric bulk of the addition will favor
orientation of the fatty acid tail downward, the more kinetically favored orientation (Hua
et al., 2016). The substitutions at X (given in Figure 58) are intended to moderate binding
affinity and solubility, and screening the substitutions looking at these two variables
would be the first step in judging these 2-AG permutations. Based upon the SAR
discussed previously, the compound should have a pronounced increase in affinity for
CB1, and the substitutions at X should serve to allow tuning of this affinity.
Exploring this concept experimentally brings its own challenges. In no particular
order: 1) addition of the fluorobenzene moiety must be accomplished at C1, not C3, and
so setting up the nucleophilic substitution with 1-fluoro-4-iodobenzene would require
"feathering" the reaction conditions so as to generate a single substitution and then
subsequent isolation and purification of the desired isomer, 2) the new compound now
possesses a chiral center, the effects of which on receptor binding were reported as
minimal (Bow and Rimoldi, 2016); however, for pharmacological development, each
isomer must be isolated and screened individually, 3) the introduction of a halogenated
benzene introduces new issues in overall compound toxicity, since halogenated benzene
compounds are implicated in numerous pathologies (Environmental Protection Agency,
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2006), and assessing receptor affinity for this compound, and any other 2-AG derivative
of interest, will face identical challenges as those encountered by previous studies
(detailed in Chapter II).
None of these issues are insurmountable; however, in combination they pose a
challenge requiring ingenuity to approach. With the publication of a crystal structure for
CB1, using mathematical models to predict an idealized, stable agonist is a clearly
favored path forward, and adapting such models to inform structural modification of 2AG to improve CB1 affinity is a rational next step. Regardless, the only true test is to
synthesize each compound and screen with the appropriate battery of tests.
Summary
The total content of this thesis has covered a broad range of topics from the sociocultural impediments to the study and use of the psycho-active constituents of C. sativa,
to the discovery and elucidation of a novel cannabinoid receptor system and the
associated endogenous ligands, to the integration and effects of the cannabinoid receptor
system in the cellular cycle, and finally, the implications of these effects in the pursuit of
using cannabinoids in cancer treatment modalities. The purpose of presenting this breadth
of information was to give the appropriate context for the reasons for undertaking this
project to begin with, and why the pursuit of an improved synthetic route for 2arachidonoyl glycerol is a desirable goal. The goal of synthesizing 2-AG is a stepping
stone on a path that hopefully leads to methods by which cannabinoids can be
incorporated into cancer treatment modalities to improve existing treatment
methodologies or even generate completely novel treatment methods. Doing this requires
a view that encompasses not just the chemical, biological, and physiological background,
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but also the sociological and legal impediments for bringing these compounds into
pharmacological treatment and distribution systems.
The breadth of the task and challenges involved can be daunting. Only further
time and research will tell if cannabinoids can be integrated into new and successful
treatment modalities, but if the current state of knowledge is anything to go by, there are
many reasons to hope. There is also much more work to be done.
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